10,000 Matching Annotations
  1. Last 7 days
    1. 74-year-old male was admitted to the Department of Cardiology, Daejeon St. Mary’s Hospital (Daejeon, Korea), for the evaluation of exertional dyspnea (New York Heart Association (NYHA) functional class III), palpitations, and bilateral leg pitting edema for several months.

      Case#: Pedigree I-1; 74-year-old Korean male; admitted for dyspnea (NYHA III), palpitations, and bilateral pitting leg edema over several months

      DiseaseAssertion: Idiopathic restrictive cardiomyopathy (RCM) with biatrial enlargement, in a family with MYBPC3-related cardiomyopathy

      FamilyInfo: Family history of heart disease with two affected daughters (II-2 and II-4), both heterozygous for the same variant and both diagnosed with HCM. Unaffected granddaughter (III-3) tested negative. Both daughters showed asymmetric septal hypertrophy on TTE (18 mm and 17 mm) with mildly dilated LA; daughter II-2 had grade I diastolic dysfunction and mild exertional chest discomfort. CMR confirmed reverse septal curvature hypertrophy consistent with HCM in both daughters, with no LGE in either.⁠

      ParentalTesting: Not performed; the proband is the index case in generation I; his parents were not evaluated. Phase established only through the daughters and granddaughter.

      CasePresentingHPOs:HP:0002094; HP:0001962; HP:0001677; HP:0001635; HP:0001639; HP:0001698

      CaseHPOFreeText: Exertional dyspnea NYHA class III, palpitations, and bilateral leg pitting edema for several months; dyspnea refractory to heart failure medication, with pulmonary venous congestion. ECG and Holter: atrial fibrillation with rare premature ventricular complexes. TTE: RCM with biatrial enlargement and small pericardial effusion. CMR: normal LV chamber size, borderline diffuse LV hypertrophy, very large atria, extensive transmural LGE in the apical wall and mid-myocardial patchy LGE in the ventricular septum. Coronary angiogram normal; no secondary cause of RCM found.⁠

      CaseNotHPOs: HP:0000822; HP:0000819; HP:0001658; HP:0001678

      CaseNotHPOFreeText: Coronary angiogram normal, so no obstructive coronary disease. No secondary cause of RCM identified; no inflammatory, infiltrative, or systemic disease found. No AV block; the rhythm disturbance was atrial fibrillation.

      CasePreviousTesting: Whole exome sequencing (Agilent SureSelect XT Human All Exon v5, Illumina HiSeq2500, GATK. Sanger sequencing of family members showed only the MYBPC3 variant tracked with disease; the other four (KALRN c.1702C>T, KCNH2 c.442C>T, SKI c.30T>G, TTN c.54293T>C) did not correlate with phenotype.⁠

      Genotyping Method: WES in the proband, with annotation via dbNSFP and Ensembl VEP; Sanger sequencing confirmed the MYBPC3 frameshift in the proband (I-1), daughters II-2 and II-4, and its absence in granddaughter III-3 (Fig. 3B).⁠

      FunctionalAnalysis: None performed. CMR showed extensive LGE in the apical LV, and the authors propose that advanced myocardial fibrosis in end-stage HCM can provoke myocardial atrophy, explaining the relatively normal LV chamber size with a predominantly restrictive phenotype hypothesis.⁠

      Variant: MYBPC3 NM_000256.3:c.3313_3314insGG (p.Ala1105Glyfs*85); heterozygous frameshift insertion; absent from gnomAD and the Korean Reference Genome Database.

      ClinVar: 1473634

      CAID: Not reported.

      Gene:MYBPC3

      HGNC: HGNC: 7551

      PMID: 33803538

      gnomAD: Absent per the authors' check of gnomAD as of 8 November 2020, and absent from KRGDB.

      AdditionalInfo: Authors conclude the MYBPC3 frameshift is the pathogenic variant, with the same allele producing RCM in the proband and HCM in both daughters; an example of pleiotropy and variable expressivity within one family. The frameshift has previously been reported in Korean HCM. Poor-prognosis features in RCM cited by the authors: male sex, age over 70, high NYHA class, and LA dimension >60 mm.

    1. subject (33-year-old female) showed regular psychophysical development

      Case#: 33 year-old female; first cardiologic evaluation at age 24 (LV wall thickness 13 mm); re-evaluated at 33 after recurrent palpitations

      DiseaseAssertion: Noonan syndrome (PTPN11) with sarcomeric hypertrophic cardiomyopathy (MYBPC3); non-obstructive HCM, mild phenotype

      FamilyInfo: Father carries the MYBPC3 c.1790G>A variant and has HCM; the PTPN11 variant was absent in both parents, consistent with de novo. Both parents and the proband's brothers underwent full cardiologic evaluation, no cardiovascular disease in the other family members. Parents declined genetic testing of the underage siblings. Grandparents (I-1, I-2) and II-2, II-3 have unknown phenotypes (pedigree Fig. 2).

      ParentalTesting: Both parents genotyped for the two proband variants (Table 1). Father heterozygous for MYBPC3 c.1790G>A; neither parent carries PTPN11 c.1510A>G, supporting de novo status. Phase between the two variants therefore established as in trans (different genes).

      CasePresentingHPOs: HP:0001639; HP:0001962; HP:0004322; HP:0000271; HP:0001647; HP:0000508

      CaseHPOFreeText: Regular psychophysical development. First echo at 24 showed mild increase in LV wall thickness (13 mm). At 33, presented with several episodes of palpitations; exam showed mild facial dysmorphisms (wide mouth, sloping forehead, prominent nasal bridge, prominent nose, low-set ears), short stature, and a systolic heart murmur. Echo: asymmetric LV hypertrophy, maximum wall thickness 16 mm at the anterior interventricular septum, mild mitral regurgitation, non-obstructive. No other cardiovascular signs.

      CaseNotHPOs: HP:0001635; HP:0001650; HP:0001642; HP:0001250

      CaseNotHPOFreeText: No heart failure, no LV outflow obstruction, no pulmonary stenosis, no other congenital heart defect. No intellectual disability; psychophysical development was regular. No other signs of cardiovascular disease on examination.

      CasePreviousTesting: NGS panel of 325 cardiomyopathy-associated genes (Supplementary Table S1); MAF threshold 5%; variants validated by Sanger sequencing; cascade testing restricted to the two proband variants.

      Genotyping Method: NGS targeted panel (Maxwell 16 DNA extraction, Agilent Alyssa analysis, Illumina Variant Interpreter, in-house pipeline) with Sanger validation; parental Sanger genotyping for the same two variants.

      FunctionalAnalysis: None performed by the authors. They cite prior HeLa cell work showing the MYBPC3 c.1790G>A change causes exon 18 inclusion in the transcript and an almost undetectable 248 bp product.

      Variant 1: PTPN11 NM_002834.3:c.1510A>G (p.Met504Val); heterozygous missense; de novo; classified pathogenic, explains Noonan syndrome

      ClinVar: Not stated in the paper; verify the current record before submitting.

      CAID: N/A

      gnomAD: Not reported in the paper; I have not checked gnomAD for this variant.

      Variant 2: MYBPC3 NM_000256.3:c.1790G>A (p.Arg597Gln); heterozygous missense; exon 18, last nucleotide of the exon, affecting a highly conserved residue and causing a splicing variation; inherited from the father

      ClinVar: Not stated in the paper; authors note it is classified pathogenic/likely pathogenic for HCM in several genetic databases.

      CAID: N/A

      gnomAD: N/A

      PMID: 32824488

      Gene: MYBPC3

      AdditionalInfo: Authors describe this as the first reported young adult with HCM and mild NS carrying variants in both PTPN11 and MYBPC3. Note the terminology problem: the abstract calls them "compound heterozygous," but the variants are in different genes on different chromosomes, so this is digenic (double heterozygosity), not compound heterozygosity. The authors argue the mild phenotype contrasts with the usual expectation that multiple sarcomeric hits worsen the disease, and that red flags justified the broad panel.

    1. 39‐year‐old man presented in 1998 with shortness of breath during exertion

      Case#: Pedigree III:2; male; HCM diagnosed clinically at age 39 (1998); heart transplant after progression to end-stage heart failure

      DiseaseAssertion: Hypertrophic cardiomyopathy (HCM), progressed to end-stage heart failure with systolic dysfunction

      FamilyInfo: No family history of heart disease reported at diagnosis; no known consanguinity. Parents deceased and unavailable for testing. 12 relatives genotyped: one brother (III:3) homozygous, seven first- and second-degree relatives heterozygous. All heterozygotes have normal ECG, normal echo, and no cardiac symptoms. Three children of generation IV (IV:7, IV:8, IV:9) still awaiting results.⁠

      ParentalTesting: Not performed; both parents deceased. Absence of consanguinity stated but not genetically confirmed; parental phase therefore inferred rather than tested.

      CasePresentingHPOs: HP:0001639; HP:0002094 (Dyspnea); HP:0001658; HP:0001678

      CaseHPOFreeText: Exertional dyspnea at age 39 with systolic murmur; IVS 26 mm, posterior wall >16 mm, LVOT peak velocity 2.8 m/s. Pacemaker 1999, extracted 2010 for infection. 2013 circumflex occlusion treated with stent (cholesterol 6.8 mmol/L, LDL 4.6 mmol/L; former smoker). Septum 27 mm, moderate systolic dysfunction, NSVT on Holter → ICD. 2014 AF with severe dyspnea; on beta-blocker, ACE inhibitor, and aldosterone antagonist. 2016 VO₂max 14 mL/kg/min; LVEDP 24 mmHg rising to 38 with exercise, pulmonary pressure 56/27 rising to 70/… systolic. Biopsy: moderate interstitial fibrosis, focal hypertrophy and atrophy, no infiltrative disease.

      CaseNotHPOs: HP:0000822; HP:0000819

      CaseNotHPOFreeText: BP normal throughout, no hypertension. No storage or infiltrative disease on biopsy. Spirometry normal. Narrow QRS, so CRT not indicated.

      CasePreviousTesting: 84-gene cardiomyopathy NGS panel (MYBPC3 100% coverage); MLPA confirmed true homozygosity rather than hemizygous deletion; Sanger cascade in 12 relatives.

      Genotyping Method: NGS panel followed by MLPA confirmation of homozygosity; Sanger for family cascade.

      FunctionalAnalysis: None performed. Biopsy showed interstitial fibrosis with hypertrophy and atrophy, no infiltrative disease. Dominant-negative mechanism proposed, untested.

      Variant: MYBPC3 NM_000256.3:c.2618C>A (p.Pro873His); homozygous missense; C7 domain. (Paper writes "c.2618 G>A" once, C>A is correct.)

      ClinVar: Not stated; conflicting interpretations noted in the literature. Pepper please verifiy for me!

      CAID: N/A

      gnomAD: AF 0.00006781 (14/206,446; 13/97,288 European non-Finnish) per the authors.

      AdditionalInfo: ACMG Class 2 (likely pathogenic) heterozygous. Authors argue homozygosity drove progression to end-stage failure; alternative triggers considered, prior myocarditis (1989) and the 2013 infarct; but judged insufficient to explain severity.

      PMID: 29663722 Gene: MYBPC3 HGNC: HGNC:7551

  2. Nov 2026
    1. The proband, a four-month-old boy, presented with polymorphic ventricular tachycardia.

      Case#: 4 month old boy

      DiseaseAssertion: Polymorphic ventricular tachycardia

      FamilyInfo: His father carried the RYR2 variant and had ventricular premature beats. His mother carried the SCN10A variant and was asymptomatic.

      ParentalTesting: Yes. Familial genetic testing showed the RYR2-A1855D variant was inherited from the father and the SCN10A-Q1362H variant was inherited from the mother.

      CasePresentingHPOs: HP:0004756

      CaseHPOFreeText: 4-month-old male presenting with polymorphic ventricular tachycardia.

      CaseNotHPOs: not reported

      CaseNotHPOFreeText: not reported

      CasePreviousTesting: Clinical cardiac evaluation followed by genetic testing

      Genotyping Method: Genetic testing identified novel heterozygous RYR2-A1855D and SCN10A-Q1362H variants.

      FunctionalAnalysis: Functional studies showed abnormal calcium handling, prolonged action potentials, increased susceptibility to early afterdepolarizations, and disrupted Ca2+ homeostasis in cells carrying both variants.

      Variant: RYR2 (heterozygous) SCN10A

      ClinVar: not found

      CAID: not found

      gnomAD: not found

      AdditionalInfo:

  3. Oct 2026
    1. three cases

      Case#: 2 (16 y, male - brother of Case 1, symptom onset/pain+movement limitation 8 y, diagnosis 16y)

      DiseaseAssertion: Scheie syndrome

      FamilyInfo: Male patient born to consanguineous parents

      CasePresentingHPOs: 0034337

      CaseHPOFreeText: claw hands with flexion contractures; electroneurology showed bilateral signs of mild median nerve suffering.

      CaseNotHPOs: HP:0000280; HP:0001510; HP:0000943

      CaseNotHPOFreeText: no coarse face, growth failure, other joint involvement, evidence of dysostosis multiplex of other bones. Normal intelligence, ophthalmologic, hearing and echocardiography, brain MRI

      CaseEnzymeAssay: 0.64 (umol/g/h)

      CaseUrineGAGs:

      CaseERT: Yes, after diagnosis at 16y CaseBMT:

      Variant1:c.1189+4A>T

      Variant1ClinVarID:

      Variant1CAID: CA2586965965

      Variant2: 1189+4A>T

      Variant2ClinVarID:

      Variant2CAID: CA2586965965

      AdditionalVariants:

      ParentalGenotype:

      PreviouslyPublished

    2. 19 years)

      Case#: 3 (19 y, male - cousin of Cases 1 and 2, symptom onset/pain+movement limittion 12y, diagnosis 19y))

      DiseaseAssertion: Scheie syndrome

      FamilyInfo: Male patient born to consanguineous parents

      CasePresentingHPOs:

      CaseHPOFreeText: electroneurology showed bilateral signs of mild median nerve suffering.

      CaseNotHPOs: 0034337;HP:0001510; HP:0000943

      CaseNotHPOFreeText: no coarse face, growth failure, other joint involvement, evidence of dysostosis multiplex of other bones. Normal intelligence, ophthalmologic, hearing and echocardiography, brain MRI

      CaseEnzymeAssay: 0.57 (umol/g/h)

      CaseUrineGAGs:

      CaseERT: Yes, after diagnosis at 19y

      CaseBMT:

      Variant1:c.1189+4A>T

      Variant1ClinVarID:

      Variant1CAID: CA2586965965

      Variant2: 1189+4A>T

      Variant2ClinVarID:

      Variant2CAID: CA2586965965

      AdditionalVariants:

      ParentalGenotype:

      PreviouslyPublished

    3. Three cases from the same family.

      Case#: 1 (18 y, female, symptom onset/pain+movement limitation 10y, carpal tunnel syndrome surgery 16y, diagnosis 18y)

      DiseaseAssertion: Scheie syndrome

      FamilyInfo: "female patient, brother, and male cousin born to consanguineous parents" Based on pedigree (Figure 4), the cousins are related through their mothers but the degree of consanguinity is not clear

      CasePresentingHPOs: 0034337

      CaseHPOFreeText: claw hands with flexion contractures; electroneurology showed bilateral signs of severe median nerve suffering.

      CaseNotHPOs: HP:0000280; HP:0001510; HP:0000943

      CaseNotHPOFreeText: no coarse face, growth failure, other joint involvement, evidence of dysostosis multiplex of other bones. Normal intelligence, ophthalmologic, hearing and echocardiography, brain MRI

      CaseEnzymeAssay: 0.36 (umol/g/h)

      CaseUrineGAGs:

      CaseERT: Yes, after diagnosis at 18y

      CaseBMT:

      Variant1:c.521delA

      Variant1ClinVarID:

      Variant1CAID: CA2586973518

      Variant2: 521delA

      Variant2ClinVarID:

      Variant2CAID: CA2586973518

      AdditionalVariants:

      ParentalGenotype:

      PreviouslyPublished

    1. An integrated multiomic approach as an excellent tool for the diagnosis of metabolic diseases: our first 3720 patients

      PMID:35614200

      Gene: IDUA

      Disease: MPS1

      Inheritance: Autosomal recessive

      A list of 11 IDUA variants identified in cases with MPS is included in Supplemental Table 6, but the variants are not linked to specific patients and are listed individually (not as genotypes). A page note has been added for each variant.

    1. plified from DNA derived from affected individuals offamily MI. In addition to the guanine residue at nucleotideposition

      Case#: Family MI, Northern European

      CasePresentingHPOs: HP:0001639

      CaseHPOFreeText:

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting:

      CaseMethod1:

      CaseMethod2:

      CaseGenotypingMethod: PCR amplification followed by Cycle Sequencing

      Variant: The nucleotide variant positions here refer to those described in the initial cloning of the gene in 1988 (PMID: 3336363), but nucleotide G579A here aligns to NM_001018005.2(TPM1):c.523G>A (p.Asp175Asn).

      ClinVar: 12456

      CAID: CA018106

      gnomAD: Grpmax FAF = 7.900e-7, SNV: 15-63060899-G-A, gnomADv4_D175N

      VariantEvidence:

      CaseAddInfo:

      CasePMIDs: PMID:8327508

    2. nucleotide position 595 in exon 5 of the a-tropomyosingene (Figure 2, left). The normal adenine residue was alsoprese

      Case#: Family MZ, Northern European

      CasePresentingHPOs: HP:0001639 ( Hypertrophic cardiomyopathy)

      CaseHPOFreeText:

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting:

      CaseMethod1:

      CaseMethod2:

      CaseGenotypingMethod: PCR amplification followed by Cycle Sequencing

      Variant: The nucleotide variant positions here refer to those described in the initial cloning of the gene in 1988 (PMID: 3336363), but nucleotide A595G here aligns to NM_001018005.2(TPM1):c.539A>G (p.Glu180Gly).

      ClinVar: 12455

      CAID: CA019017

      gnomAD: 15-63060915-A-G not in gnomAD v4.0.0

      VariantEvidence:

      CaseAddInfo:

      CasePMIDs: PMID:8327508

    1. a proband

      Case#: Male, first evaluated at 3.5 years, diagnostic studies described in paper at age 4.5 years, at time of report 11 years

      DiseaseAssertion: Mucopolysaccharidosis Type I and Type II

      FamilyInfo:Clinically normal sister, mother and father; parents denied consanguinity; extensive histocompatibility typing of all family members confirmed relationships and did not suggest consanguinity; Maternal uncle died at 11 years having "coarse facial features" but not diagnostic testing. Pedigree, Figure 7, page 82.

      CasePresentingHPOs: HP:0000943 (dysostosis multiplex); HP:0000280 (course facial features)

      CaseHPOFreeText: at 3.5 years "...gross motor delay, mild expressive language delay, and progressive changes in facial features and joints...noted to be a noisy breather and have a history of frequent ear infections...prominent metopic suture and facial features were said to be coarsened" Height 50th%, weight 95th%, head circumference >98th%. At 11 years of age reported to show progressive intellectual deterioration.

      CaseNotHPOs:

      CaseEnzymeAssay: Table 2 (page 79): leukocyte IDUA (alpha-L) activity absent (<1.0 nmol/mg/h), plasma IDUA alpha-L <0.20 MU/ml/h); plasma IDS activity was undetectable (0.0 U/mg/h)

      CaseUrineAssay:Not reported

      CaseERT:Don't know

      CaseBMT:Don't know

      Variant1:IDUA W402X

      Variant1ClinVarID:11908

      Variant1CAID:

      Variant2: IDUA A300T

      Variant2ClinVarID: 11923

      Variant2CAID:

      AdditionalVariants: IDS R468W (missense 1402C-->T), ClinVarID: 10497

      ParentalGenoype:Mother, IDUA A300T and IDS R468W; Father, IDUA W402X

      PreviouslyPublished:

    1. An Integrated Computational Framework to Assess the Mutational Landscape of α-L-Iduronidase IDUA Gene

      Free, full-text NOT available. Text obtained through a University account and annotations added to the free PubMed abstract.

      IDUA variants were pulled from various public databases and subjected to in silico analyses. No individual-level patient data (e.g., phenotypes) are provided.

    1. Agreement between the results of meta-analyses from case reports and from clinical studies regarding the efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age: An example of case reports meta-analyses as an useful tool for evidence-based medicine in rare diseases

      Free, full-text NOT available. Full text was retrieved via a university account, and the free PubMed abstract was annotated.

      This paper describes a meta-analysis of previously published data for 11 patients. PMID's for prior published reports:

      25864295, 21482163, 22303797, 21167740, 19894140, 18792977, 18546328, 16601901

      The above PMID's are all included in the IDUA Excel file.

      Three cited manuscripts do not have a PMID and are not included in the IDUA Excel file. Links to these papers are provided below:

      https://doi.org/10.1016/j.farma.2010.11.005 (in Spanish)

      https://doi.org/10.1007/s10545-005-0211-x

      https://doi.org/10.1016/j.jfma.2014.05.009

  4. Sep 2026
    1. Case 4

      Case#: Case 4, Sex: Female, Age:34

      DiseaseAssertion: STGD

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Text mentions BCVA 20/100 in both eyes later became 20/240. Bilateral atrophic-appearing foveal lesions associated with yellowish-white fundus flecks at the posterior pole. Subnormal scotopic and photopic responses. Subretinal fibrosis in left eye. Hypofluorescence due to hyperplasia of RPE in left eye.

      CaseNotHPOs:n/a

      CaseNotHPOFreeText: No ocular trauma.

      Genotyping Method: genetic analysis

      PreviouslyPublished: n/a

      Variant: Variant is a heterozygous mutation given as NM_000350.3(ABCA4):c.3113C>T (p.Ala1038Val)

      ClinVar: Variation ID: 7894

      CAID: CA119135

      SupplementalData: n/a

    2. Case 2

      Case#: Case 2, Sex: Male, Age:20

      DiseaseAssertion: STGD

      FamilyInfo: n/a

      CasePresentingHPOs: HP:0007663, HP:0007401

      CaseHPOFreeText: Text mentions visual acuity of 20/32 in right eye and 20/50 in left eye but later degrades to 20/200 in both eyes. pigmented changes in macula associated with flecks. Area of subretinal fibrosis in right eye. Subnormal scotopic and photopic responses. Instable fixation in both eyes with low retinal mean sensitivity. Hypofluorescent central area corresponding to macular atrophy and corresponding to flecks. Atrophic areas, some with pigment, localized in the temporal sector of the left eye which have become areas of subretinal fibrosis.

      CaseNotHPOs:n/a

      CaseNotHPOFreeText: Anterior segment showed a healthy ocular adnexa, and specular, transparent and 'in situ' lens, absence of any ocular trauma.

      Genotyping Method: genetic analysis

      PreviouslyPublished: n/a

      Variant: Variant is a homozygous mutation given as NM_000350.3(ABCA4):c.571-2A>T

      ClinVar: Variation ID: 1048133

      CAID: CA958800

      SupplementalData: n/a

    3. Case 1

      Case#: Case1, Sex:Female, Age:35

      DiseaseAssertion: STGD

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Clinical Notes: the patient reported an ocular trauma in the right eye, which required hospitalization and caused sudden loss of vision at the age of 9 years. In 1998, at our first observation, visual acuity was 20/1,000 in the right eye and 20/600 in the left eye.

      CaseNotHPOs:n/a

      CaseNotHPOFreeText: n/a

      Genotyping Method: genetic analysis

      PreviouslyPublished: n/a

      Variant: Variant is a heterozygous mutation given as (N965S/G1961E); NM_000350.3(ABCA4):c.2894A>G (p.Asn965Ser) /NM_000350.3(ABCA4):c.5882G>A (p.Gly1961Glu)

      ClinVar: Variation ID: 236096 / Variation ID: 7888

      SupplementalData: n/a

    4. Case 3

      Case#: Case 3, Sex: Male, Age:21

      DiseaseAssertion: STGD

      FamilyInfo: n/a

      CasePresentingHPOs:

      CaseHPOFreeText: Text mentions BCVA of 20/200 in both eyes. Pigmentary changes in macula associated with flecks, small inferior juxta-papillar area of subretinal fibrosis in right eye, left eye legion localized in posterior pole macula temporally. Instable fixation in right eye. Low retinal mean sensitivity in both eyes.

      CaseNotHPOs:n/a

      CaseNotHPOFreeText: Healthy ocular adnexa and specular transparent and 'in situ' lens. Visual acuity stable. Stable fixation in left eye.

      Genotyping Method: genetic analysis

      PreviouslyPublished: n/a

      Variant: Variant is a heterozygous mutation given as NM_000350.3(ABCA4):c.3212C>T (p.Ser1071Leu) / NM_000350.3(ABCA4):c.667A>C (p.Lys223Gln) / NM_000350.3(ABCA4):c.3607G>A (p.Gly1203Arg)

      ClinVar: Variation ID: 99208 / Variation ID: 845426/ Variation ID: 417989

      SupplementalData: n/a

    1. STGD-01

      Case#: Case1, Sex:Male, Age:19

      DiseaseAssertion: STGD

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Clinical Notes: Peripapillary sparing, discrete flecks; nummular atrophy. General notes: Panretinal cone dysfunction with preserved rod function was documented by ERG

      CaseNotHPOs:n/a

      CaseNotHPOFreeText: n/a

      Genotyping Method: Whole exome sequencing data generation. Additional sequencing targeted amplification fo PRPH2 and ELOVL4 using PCR.

      PreviouslyPublished: n/a

      Variant: Variant 1 given as p.N965S; NM_000350.3(ABCA4):c.2894A>G (p.Asn965Ser). Variant 2 given as p.R2038W; NM_000350.3(ABCA4):c.6112C>T (p.Arg2038Trp)

      ClinVar: Variation ID: 236096; Variation ID: 99430

      CAID: CA958124; CA227368

      SupplementalData: Proband variant information given in Table 1.

    2. STGD-06

      Case#: Case 6, Sex:Female, Age:34

      DiseaseAssertion: STGD

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Clinical Notes: Classic Stargardt. General notes: participant had classic features of STGD and field ERG showed abnormal cone responses with preserved rod function.

      CaseNotHPOs:n/a

      CaseNotHPOFreeText: n/a

      Genotyping Method: Exome sequencing data generation. Additional sequencing targeted amplification fo PRPH2 and ELOVL4 using PCR.

      PreviouslyPublished: n/a

      Variant: ABCA4, NM_000350.3(ABCA4):c.2966T>C (p.Val989Ala)

      ClinVar: Variation ID: 99180

      SupplementalData: Proband variant information given in Table 1.

    3. STGD-02

      Case#: Case2, Sex:Female, Age:15

      DiseaseAssertion: STGD

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Clinical Notes: Few yellowish Flecks without autofluorescence. General notes: participant presented with atypical macular degeneration.

      CaseNotHPOs:n/a

      CaseNotHPOFreeText: n/a

      Genotyping Method: Exome sequencing data generation. Additional sequencing targeted amplification fo PRPH2 and ELOVL4 using PCR.

      PreviouslyPublished: n/a

      Variant: Variant 1 given as p.G1961E; NM_000350.3:c.5882G>A p.(Gly1961Glu) . Variant 2 given as p.Q636X; NM_000350.3(ABCA4):c.1906C>T (p.Gln636Ter).

      ClinVar: Variation ID: 7888 ; Variation ID: 265012

      CAID: ; CA10588302

      SupplementalData: Proband variant information given in Table 1.

    1. ABCR Gene Analysis in Familial Exudative Age-Related Macular Degeneration

      PMID: 10634626 Gene: ABCA4 HGNCID: HGNC:34

      Fifty-two unrelated French patients referred to the Eye University Clinic of Creteil for unilateral or bilateral exudative AMD due to any type of choroidal neovascularization (well-defined, occult, or vascularized pigment epithelium detachment) were included in this study.

      SSCP analysis in a control population, obtained from 90 unrelated French individuals without any complaint of visual impairment. Our control group was not age- or sex-matched, and no ophthalmological examination was performed for these individuals.

      MonDO:

      Case: DiseaseAssertion: Age-related macular degeneration FamilyInfo: CasePresentingHPOs: CaseHPOFreeText: CaseNOTHPOs: CaseNOTHPOFreeText: CasePreviousTesting:

      GenotypingMethod: entire coding sequence of the ABCR gene using a combination of single-strand conformation polymorphism (SSCP) and direct sequence analysis of each exon

      Variant: "ABCR" (ABCA4), p.Ser2255ile

    1. A 43-year-old white female

      Case#: 43 year old woman II:2

      DiseaseAssertion: Stargardt disease (STGD1)

      FamilyInfo: none of family had co-existing systemic disorders, father carried variant, probands affected suster did not

      CasePresentingHPOs:HP:0000007

      CaseHPOFreeText: loss of ellipsoid zone, mascular dystrophy with features of bull's eye maculopathy,

      CaseNotHPOs: na

      CaseNotHPOFreeText: na

      Genotyping Method: sanger sequencing

      PreviouslyPublished: n/a

      Variant: c.4685 T > C, p.(I1562T)

      ClinVar: not found

      CAID: not found

      SupplementalData: probands affected sister did not carry the ABAA4 variant, indicating ABCA4 was not relevant to mascular dystrophy in family, CRX variant was also found

    1. Molecular analysis of ABCA4 and CRB1 genes in a Spanish family segregating both Stargardt disease and autosomal recessive retinitis pigmentosa

      PMID: 18334942

      Gene: ABCA4

      HGNC ID: 34

      Case#: patient 33, male, Spanish

      DiseaseAssertion: STGD

      FamilyInfo: Figure 1. Both parents and two siblings of the proband were heterozygous for ABCA4 c.5413A>G allele. Sister affected despite heterozygosity.

      CasePresentingHPOs: HP:0007663, HP:0030786, HP:0007722

      CaseHPOFreeText: myopia, astigmatism, opafication of posterior pole of lens, hyperpigmentation, a few central yellowish flecks, shallow peripheral scotomas in both eyes, full-field ERG response showed slightly reduced—but still within the normal range—amplitudes for rod, mixed cone-rod, cone single flash, and cone flicker, respectively.

      CasePreviousTesting: n/a

      GenotypingMethod: microarray

      PreviouslyPublished: 11385708, 12442277

      Variant: ABCA4 p.Asn1805Asp (c.5413A>G)

      ClinVar: 99373 https://www.ncbi.nlm.nih.gov/clinvar/variation/99373/?term=%22ABCA4%22%5BGENE%5D+AND+%22p.Asn1805Asp%22%5BVARNAME%5D+AND+%22(c.5413A%3EG)%22%5BVARNAME%5D

      gnomAD: 0.000009292 https://gnomad.broadinstitute.org/variant/1-94014590-T-C?dataset=gnomad_r4

    2. Molecular analysis of ABCA4 and CRB1 genes in a Spanish family segregating both Stargardt disease and autosomal recessive retinitis pigmentosa

      PMID: 18334942

      Gene: ABCA4

      HGNCID: 34

      Case#: patient 26, female, Spanish

      DiseaseAssertion: early onset RP

      FamilyInfo: Figure 1. One brother homozygous for ABCA4 c.5413A.G allele, parents and one brother heterozygous for ABCA4 c.5413A>G allele. All three brothers and father carriers of p.Cys948Tyr allele on the CRB1 gene. Mother heterozygous for p. Trp822ter (c.2465G>A)

      CasePresentingHPOs: HP:0000662, HP:0001133, HP:0007663,

      CaseHPOFreeText: hyperopia, astigmatism, nystagmus, roundish pigments distributed across entire retina including peripheral retina, posterior pole, and macular region, filiform constriction on retinal vessels.

      CasePreviousTesting: N/A

      GenotypingMethod: Microarray

      PreviouslyPublished: 11385708, 12442277

      Variant: ABCA4 p.Asn1805Asp (c.5413A>G)

      ClinVar: 99373 https://www.ncbi.nlm.nih.gov/clinvar/variation/99373/?term=%22ABCA4%22%5BGENE%5D+AND+%22p.Asn1805Asp%22%5BVARNAME%5D+AND+%22(c.5413A%3EG)%22%5BVARNAME%5D

      gnomAD: 0.000009292 https://gnomad.broadinstitute.org/variant/1-94014590-T-C?dataset=gnomad_r4

    1. In case 71674, diagnosed with arRD, along with a recurrent nonsense mutation (p.Trp663*, HGMD Accession = {"type":"entrez-nucleotide","attrs":{"text":"CM003370","term_id":"909078994","term_text":"CM003370"}}CM003370), a novel splice-site variant was identified (c.2160 + 1 G > T) (Fig. 3a). This variant is predicted to lead to skipping of exon 14 in the ABCA4 transcript. The patient inherited one mutant allele from each parent.

      Patient 71674: Female, Swiss, 13 years old. bi-allelic variants in ABCA4, diagnosed with Retinal dystrophy DD: Retinitis pigmentosa

      Figure 3: Segregation analysis performed on family samples GenotypingMethod: Whole exome sequencing performed on HiSeq2000 and NextSeq500 (252 genes)

      Multiple Variants: VPS13B NM_017890.4:c.897 8A>G:p.Asn2993Ser Heterozygous CM041280

      PCDH15 NM_001142763.1:c. 4329_4337del:p.Pro 1446_Pro1448del Heterozygous

      DHX38 NM_014003.3:c.366 2C>T:p.Thr1221Met Heterozygous

      USH1G NM_173477.4:c.310 A>G:p.Met104Val Heterozygous

    1. Carrier frequency analysis of mutations causing autosomal-recessive-inherited retinal diseases in the Israeli population

      PMID: 29706639

      Gene: ABCA4

      HGNCID: HGNC:34

      MonDO: MONDO:0019353

      Bioinformatic analyses of an SQL-based database containing 12272 variants that appear in 178 IRD genes in 5706 individuals of Ashkenazi Jewish origin based on the gnomAD database (version 2) and variants that were published in the scientific literature that was extracted from HGMD. Authors extracted information regarding IRD variants from various sources (including data of 5706 Ashkenazi Jewish (AJ) samples and a large cohort of Israeli patients with IRDs) to estimate carrier frequency of IRD mutations in different subpopulations in Israel. Two major databases aiming to estimate carrier frequency of IRD mutations in the Israeli population (Fig. 1): “gnomAD-AJ-IRD DB” containing data of 5706 AJ controls extracted from gnomAD and “HW-IRD DB” containing data extracted from our cohort of Israeli patients with IRDs.

      See Fig 2 for breakdown of variants analyzed.

      The final DB (IRDB) (Fig. 1 and Table S7) includes all 399 variants from “gnomAD-AJ-IRD DB” and “HW-IRD DB” that were considered here as pathogenic mutations in 111 known IRD genes.

      To establish the “HW-IRD DB” (Fig. 1), we collected data on Israeli IRD patients with a known cause of disease (a cohort of >2000 IRD families). The HW-IRD DB includes 289 pathogenic mutations (Fig. 1) that were identified in IRD patients who have biallelic variants.

      SupplementalData: S7, carrier frequency data for each mutation in all nine studied subpopulations. Carrier frequency was calculated as 2pq where p = 1 − q and q was calculated as the root square of the number of homozygous patients plus half the number of compound heterozygous patients divided by the population size

      Variant: NM_000350.2:c.4895dup,p.Asn1632fs

      CAID: CA915941330

      Case: Ashkenazi Jewish patient with inherited retinal disease, STGD, CRD

      CasePresentingHPOs: HP:0000548 (Cone/cone-rod dystrophy, CRD)

      CaseHPOFreeText: Stargardt disease (STGD)

    1. A 19-year-old female

      Case#: 19 year old woman

      DiseaseAssertion: Stargardt disease (STGD)

      FamilyInfo: no family history of ocular disease

      CasePresentingHPOs:HP:0025158

      CaseHPOFreeText:20/25 in the right eye and 20/25-1 in the left eye, small irregular perifoveal lesions of both increased and decreased autofluorescence

      CaseNotHPOs:na

      CaseNotHPOFreeText:na

      Genotyping Method: next gen sequencing

      PreviouslyPublished: na

      Variant: c.6079C > T, p.(Leu2027Phe) c.4139C > T, p.(Pro1380Leu)

      ClinVar: not found not found

      CAID: not found not found

      SupplementalData: “black shadow” in the right eye after getting hit by a volley ball

    1. Mutations of the retinal specific ATP binding transporter gene (ABCR) in a single family segregating both autosomal recessive retinitis pigmentosa RP19 and Stargardt disease: evidence of clinical heterogeneity at this locus

      PMID: 10874631

      Gene: ABCA4

      HGNC ID: 34

      Case#: patient 34, female

      DiseaseAssertion: RP19

      FamilyInfo: paternal first cousin with STGD, healthy father heterozygous for 1938-1 G>A splice mutation, mother homozygous for normal allele

      CasePresentingHPOs: HP:0000662, HP:0007663, HP:0007737, HP:0001133

      CaseHPOFreeText: choriocapillaris atrophy, severe concentric reduction of the visual field, abrogation of rod function

      Genotyping Method: PRISMTM Ready Reaction Sequencing Kit on an automatic fluorometric DNA sequencer

      PreviouslyPublished: N/A

      Variant: NM_000350.3(ABCA4):c.1938-1G>A

      ClinVar: 99106 https://www.ncbi.nlm.nih.gov/clinvar/variation/99106/?term=%22ABCA4%22%5BGENE%5D+AND+%22(c.1938-1G%3EA)%22%5BVARNAME%5D

      gnomAD: 0.000002488 https://gnomad.broadinstitute.org/variant/1-94060760-C-T?dataset=gnomad_r4

    2. Mutations of the retinal specific ATP binding transporter gene (ABCR) in a single family segregating both autosomal recessive retinitis pigmentosa RP19 and Stargardt disease: evidence of clinical heterogeneity at this locus

      PMID: 10874631

      Gene: ABCA4

      HGNC ID: 34

      Case#: patient 34, female

      DiseaseAssertion: STGD

      FamilyInfo: paternal first cousin with RP19, healthy father heterozygous for 1938-1 G>A splice mutation

      CasePresentingHPOs: HP:0007663, HP:0000608, HP:0000603,

      CaseHPOFreeText: yellowish flecks

      Genotyping Method: PRISMTM Ready Reaction Sequencing Kit on an automatic fluorometric DNA sequencer

      PreviouslyPublished: N/A

      Variant: NM_000350.3(ABCA4):c.1938-1G>A

      ClinVar: 99106 https://www.ncbi.nlm.nih.gov/clinvar/variation/99106/?term=%22ABCA4%22%5BGENE%5D+AND+%22(c.1938-1G%3EA)%22%5BVARNAME%5D

      gnomAD: 0.000002488 https://gnomad.broadinstitute.org/variant/1-94060760-C-T?dataset=gnomad_r4

    1. Retinal Phenotypes in Patients Homozygous for the G1961E Mutation in the ABCA4 Gene

      PMID: 22661473

      Gene: ABCA4

      HGNCID: HGNC:34

      Stage I disease was characterized by central macular atrophy with parafoveal or perifoveal flecks. Where flecks were more numerous and extended anterior to the vascular arcades and/or nasal to the optic disc, then patients were classified as having stage II disease. Although partial resorption of flecks may be present in this stage, more complete resorption of flecks was indicative of stage III disease with choriocapillaris atrophy also within the macula. Widespread RPE and chorioretinal atrophy throughout the fundus defined stage IV disease.27 Based on this classification system, the patients in our study were subdivided into 2 groups, that is those with milder disease (stage I or II) and those with more severe disease (stage III or IV) phenotypes.

    1. The proband

      Case#:case 1 II:4

      DiseaseAssertion: Stargardt disease (STGD1)

      FamilyInfo: mother has identical phenotype as proband, dad and sister asymptomatic, brother was symptomatic at 8 years old, other brother symptomatic at 15 years old.

      CasePresentingHPOs: HP:0000007

      CaseHPOFreeText: at age 50, with central visual imparement in right eye, 20/40 right, 20/20 left, linear and branching hyperautofluorescent subretinal deposits and extrafoveal RPE atrophy in both eyes,

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      Genotyping Method:

      PreviouslyPublished: n/a

      Variant: c.6031_6044delins18M/p.(Ile2003LeufsTer41)

      ClinVar: not found

      CAID: not found

      SupplementalData:

    1. ABCA4-associated retinopathy complicated by didanosine-associated retinal toxicity

      PMID: 41561667

      Gene: ABCA4

      HGNC ID: 34

      Case#: patient 66, male, Italy

      DiseaseAssertion: STGD

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0000505, HP:0000551, HP:0000546

      CaseHPOFreeText: best-corrected visual acuity (BCVA) was 20/400 in both eyes, mild myopia, both eyes were pseudophakic, extensive bilateral chorioretinal atrophy involving both the posterior pole and the peripheral retina, widespread mottled hypoautofluorescence in the mid-periphery, along with pronounced macular hypoautofluorescence, significant central retinal thinning, an enlarged foveal depression, outer retinal hyper-reflectivity associated with extensive atrophy of both the RPE and the underlying choroid, dense epiretinal membrane (ERM) was also identified in the right eye, large central hypofluorescent zone involving the macular region and extending beyond the vascular arcades

      CasePreviousTesting: n/a

      GenotypingMethod: Next-Generation Sequencing

      PreviouslyPublished: n/a

      Variant: c.1714C > T p. (Arg572∗)

      ClinVar: 620085 https://www.ncbi.nlm.nih.gov/clinvar/variation/620085/?term=620085%5BVariation+ID%5D

      gnomAD: 0.000001859 https://gnomad.broadinstitute.org/variant/1-94063158-G-A?dataset=gnomad_r4

      Variant: c.2461T > A p. (Trp821Arg)

      ClinVar: 99136 https://www.ncbi.nlm.nih.gov/clinvar/variation/99136/?term=99136%5BVariation+ID%5D

      gnomAD: 0.000008054 https://gnomad.broadinstitute.org/variant/1-94055237-A-T?dataset=gnomad_r4

      Variant: c.4417C>А p. (Leu1473Met)

      ClinVar: 546600 https://www.ncbi.nlm.nih.gov/clinvar/variation/546600/?term=546600%5BVariation+ID%5D

      gnomAD: 0.00005762 https://gnomad.broadinstitute.org/variant/1-94029567-G-T?dataset=gnomad_r4

    1. Antioxidant Saffron and Central Retinal Function in ABCA4-Related Stargardt Macular Dystrophy

      PMID: 31618812

      Gene: ABCA4

      HGNCID: HGNC:34

      Patients: a group of 31 Stargardt disease/fundus flavimaculatus patients (14 males, 17 females) with an established ABCA4 genotype, accumulated prospectively over an interval of 12 months at the outpatient service of the Institution, were included in this study.

      MonDO: MONDO:0019353

      CaseInfo: Case 11, Male, 12yo. Compound het c.5882G > A; p.Gly1961glu (Pathogenic in ClinVar); c.6764G > T,p.Ser2255Ile

      DiseaseAssertion: Stargardt disease/fundus flavimaculatus

      FamilyInfo: Not provided

      CasePresentingHPOs: HP:0007769, HP:0000608, HP:0012045 (Peripheral retinal degeneration, Macular degeneration, Retinal flecks)

      CaseHPOFreeText: cone-rod pattern of retinal dysfunction

      GenotypingMethod: Mutation screening was performed by single-strand conformation polymorphism (SSCP) strategy of the whole coding region of ABCA4. Direct sequencing was also performed on siblings of probands and parents, when available, to confirm segregation of alleles.

      MultipleGeneVariants: (1) GeneName: ABCA4

      (1)Variant: c.5882G > A; p.Gly1961glu

      (1) CAID: CA119132

      (1) gnomAD: 0.01250 (gnomadv4.0.0, Grpmax Filtering AF, South Asian) https://gnomad.broadinstitute.org/variant/1-94008251-C-T?dataset=gnomad_r4

      (2) GeneName: ABCA4

      (2) Variant: c.6764G>T (p.Ser2255Ile)

      (2) CAID: CA202970

      (2) gnomAD: 0.4845 (gnomadv4.0.0, Grpmax Filtering AF, African/African-American) https://gnomad.broadinstitute.org/variant/1-93996161-C-A?dataset=gnomad_r4

    1. A nationwide genetic analysis of inherited retinal diseases in Israel as assessed by the Israeli inherited retinal disease consortium (IIRDC)

      PMID: 31456290

      Gene: ABCA4

      HGNCID: HGNC:34

      SupplementalData: as applicable Table S2. Variant found in cohort of 2,420 families including 3,413 individuals with inherited retinal diseases in Israel. Likely, this is the same family reported in PMID 29706639.

      Total number of families: 1; phenotype/s: CRD; NM_000350.2:c.4895dup, p.(Asn1632Lysfs*14)

    1. proband at age 5, targeted testing of ABCA4

      Case#: 1

      DiseaseAssertion: stargardt disease originally but didn;t have fishtail flecks

      FamilyInfo: both unaffected parents carrying heterozygous MFSD8 variants

      CasePresentingHPOs:HP:0001272

      CaseHPOFreeText:at 5 years old BCVA was measured at a Snellen equivalent at 0.13 in both eyes, at age 8, BCVA had decreased to 0.07 in both eyes, complete absence of all retinal responses on full‐field flash ERG, No fishtail flecks typical of Stargardt disease were observed

      CaseNotHPOs: n/a

      CaseNotHPOFreeText:n/a

      Genotyping Method: HaloPlex target enrichment kit amplified and sequenced using illumina, then WES

      PreviouslyPublished: n/a

      Variant: c.3113C>T p.(Ala1038Val)

      ClinVar: https://www.ncbi.nlm.nih.gov/clinvar/variation/7894/

      SupplementalData: MFSD8 variants identified

    1. Genotype/Phenotype analysis of a photoreceptor-specific ATP-binding cassette transporter gene, ABCR, in Stargardt disease.

      Analysis of ABCA4 variants in 150 families with Stargardt disease. Most of which were of northern or central European ancestry. For comparison, 220 racially matched individuals with no personal history or known family history of STGD served as controls (Anderson et al. 1995; Allikmets et al. 1997b).

      PMID: 9973280

      Gene: ABCA4

      HGNCID: HGNC:34

      GenotypingMethod: combined SSCP and heteroduplex analyses of all 50 exons of ABCA4, Sanger sequencing

      Pedigree AR417: onset at 8 years 2 segregations, 2 out of 3 offspring affected by STGD, parents and grandmother unaffected Variant: G1961E, A1038V CAID: CA119132, CA119135)

      Pedigree AR427: onset at 12 years 1 segregation, 1 out of 2 offspring affected by STGD, parents unaffected Variant: G1961E, C75G CAID: CA119132, CA226985

      Pedigree AR370: onset at 13 years 1 segregation, 1 out of 3 offspring affected by STGD, parents and grandparents unaffected Variant: G1961E, C1490Y CAID: CA119132, CA227198

      Pedigree AR 218: onset at 14 years family history of AMD, was first reported by Anderson et al. [1995] Variant: G1961E, 2160+1G>C CAID: CA119132, CA226984

      Pedigree AR 373: onset at 19 years 2 segregations, 2 out of 3 offspring affected by STGD, parents and grandparents unaffected Variant: G1961E, 4253+5G>T CAID: CA119132, CA227174

      Pedigree AR 274: onset at 20 years 1 segregation, 1 out of 4 siblings affected by STGD, parents and grandparents unaffected Variant: G1961E, A1038V CAID: CA119132, CA119135

  5. Jul 2026
  6. Jun 2026
  7. May 2026
  8. Apr 2026
    1. proband at age 5, targeted testing of ABCA4

      Case#: 1

      DiseaseAssertion: stargardt disease originally but didn;t have fishtail flecks

      FamilyInfo: both unaffected parents carrying heterozygous MFSD8 variants

      CasePresentingHPOs:HP:0001272

      CaseHPOFreeText:at 5 years old BCVA was measured at a Snellen equivalent at 0.13 in both eyes, at age 8, BCVA had decreased to 0.07 in both eyes, complete absence of all retinal responses on full‐field flash ERG, No fishtail flecks typical of Stargardt disease were observed

      CaseNotHPOs: n/a

      CaseNotHPOFreeText:n/a

      Genotyping Method: HaloPlex target enrichment kit amplified and sequenced using illumina, then WES

      PreviouslyPublished: n/a

      Variant: c.3113C>T p.(Ala1038Val)

      ClinVar: https://www.ncbi.nlm.nih.gov/clinvar/variation/7894/

      SupplementalData: MFSD8 variants identified

  9. Mar 2026
    1. A 19-year-old female

      Case#: 19 year old woman

      DiseaseAssertion: Stargardt disease (STGD)

      FamilyInfo: no family history of ocular disease

      CasePresentingHPOs:HP:0025158

      CaseHPOFreeText:20/25 in the right eye and 20/25-1 in the left eye, small irregular perifoveal lesions of both increased and decreased autofluorescence

      CaseNotHPOs:na

      CaseNotHPOFreeText:na

      Genotyping Method: next gen sequencing

      PreviouslyPublished: na

      Variant: c.6079C > T, p.(Leu2027Phe) c.4139C > T, p.(Pro1380Leu)

      ClinVar: not found not found

      CAID: not found not found

      SupplementalData: “black shadow” in the right eye after getting hit by a volley ball

    1. A 43-year-old white female

      Case#: 43 year old woman II:2

      DiseaseAssertion: Stargardt disease (STGD1)

      FamilyInfo: none of family had co-existing systemic disorders, father carried variant, probands affected suster did not

      CasePresentingHPOs:HP:0000007

      CaseHPOFreeText: loss of ellipsoid zone, mascular dystrophy with features of bull's eye maculopathy,

      CaseNotHPOs: na

      CaseNotHPOFreeText: na

      Genotyping Method: sanger sequencing

      PreviouslyPublished: n/a

      Variant: c.4685 T > C, p.(I1562T)

      ClinVar: not found

      CAID: not found

      SupplementalData: probands affected sister did not carry the ABAA4 variant, indicating ABCA4 was not relevant to mascular dystrophy in family, CRX variant was also found

    1. The proband

      Case#:case 1 II:4

      DiseaseAssertion: Stargardt disease (STGD1)

      FamilyInfo: mother has identical phenotype as proband, dad and sister asymptomatic, brother was symptomatic at 8 years old, other brother symptomatic at 15 years old.

      CasePresentingHPOs: HP:0000007

      CaseHPOFreeText: at age 50, with central visual imparement in right eye, 20/40 right, 20/20 left, linear and branching hyperautofluorescent subretinal deposits and extrafoveal RPE atrophy in both eyes,

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      Genotyping Method:

      PreviouslyPublished: n/a

      Variant: c.6031_6044delins18M/p.(Ile2003LeufsTer41)

      ClinVar: not found

      CAID: not found

      SupplementalData:

  10. Feb 2026
    1. A10M c.4139C>T:p(P1380L

      Case#: 10 years old

      DiseaseAssertion:See Table 1

      FamilyInfo: Not Mentioned

      CasePresentingHPOs: Not specified

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/a

      CasePreviousTesting: See Table 2

      Variant: NM_000350.3(ABCA4):c.4139C>T (p.Pro1380Leu)

      ClinVar: 7904 https://www.ncbi.nlm.nih.gov/clinvar/variation/7904/

      CAID: CA129033

      gnomAD: 0.00030430 https://gnomad.broadinstitute.org/variant/chr1-94031110-G-A?dataset=gnomad_r4

      SupplementalData: Table 2

    2. A01Fa c.4793C>A:p(A1598D)

      Case#: Age is not specified (Age of onset: 15 years old, with the time from onset: 8 years)

      DiseaseAssertion: Presented with macular flecks and alterations in the retinal pigment epithelium (RPE) subretinal deposits.

      FamilyInfo: Consanguinity within the family

      CasePresentingHPOs: HP:0000608, HP:0008035 (Macular Degeneration, Retinis pigmentosa inversa)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Visual Acuity: 20/20

      CasePreviousTesting: See Table 2

      Variant: NM_000350.3(ABCA4):C.4793C>A (p.Ala1598Asp)

      ClinVar: 99321 https://www.ncbi.nlm.nih.gov/clinvar/variation/99321/

      CAID: CA227239

      gnomAD: 0.00002631 https://gnomad.broadinstitute.org/variant/1-94021695-G-T?dataset=gnomad_r3

      SupplementalData: Table 2, Results Section

  11. Nov 2025
  12. Oct 2025
  13. Jan 2025
    1. Case: only patient, female,

      Disease Assertion: UCD/OTCD

      Family Info:

      Case Presenting HPOs: HP:0011463 Childhood onset, hyperammonemia (HP:0001987), oroticaciduria (HP:0003218), low plasma citrulline (HP:0003572), vomiting (HP:0002013),

      Case HPO FreeText : episodes of nausea, stomachache and temporary elevated trans- aminase

      Case NOT HPOs:

      Case NOT HPO Free Text: Sanger sequencing revealed no pathogenic mutation. real-time PCR was conducted on blood DNA from the patient and a male control subject using the Applied Biosystems 7300 real time PCR system (Thermo Fisher Scientific). Several primer pairs were designed for OTC (upstream of exon 1 and intron 6) and RPP30 that was used as an autosomal single copy gene reference to generate amplicons suitable for real-time PCR

      Test results plasma ammonia: 220 μg/dl (ref 12~ 60 μg/dl) plasma glutamine:1212 nmol/ml (ref 420–700) plasma citrulline: 18.4 nmol/ml (ref 17–43), urinary orotate: 234.3 μmol/g Cr (ref 4.7 ~ 15.9 μmol/g creatinine) Arg: 32.2 nmol/ml (ref 54–130).

      Case Previous Testing:

      Supplemental Data: Genetic analysis section,

      Notes: No variant mutation detected but was found first documented case of OTCD caused by an exonic duplication (exons 1 to 6) of the OTC gene. Further analysis indicated that it resulted from complex rearrangements.

      Treatment: protein-restricted diet and by oral sodium phenylbutyrate and arginine.

      Variant: NM_000531.6:-

      ClinVarID: -

      CAID: -

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

  14. Oct 2024
    1. Case: patient is named case #2, male

      Disease Assertion: UCD/OTCD

      Family Info:

      Case Presenting HPOs: Hyperammonemia (HP:0001987), oriticaciduria (HP:0003218), low plasma citrulline (HP:0003572), neonatal onset(HP:0003623), Hyperglutaminemia (HP:0003217)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: GDNA was isolated from lymphocytes. To examine the small mutations in the coding region of the OTC gene, all 10 exons and their flanking intron regions were amplified using PCR, and the nucleotide sequences of the amplified products were determined. To determine the intron 5 sequence of case 2, PCR was performed using primers OTCex5F and OTCint5R, and primers OTCint5F and OTCex6R (Table 1, Fig. 3). The amplified products were subcloned into the pT7 vector and the inserted DNA was sequenced using an automated DNA sequencer. Allopurinol test

      Supplemental Data: TABLE 1, Notes:

      Variant: NM_000531.6: c.540+265G>A

      ClinVarID: NA

      CAID: CA658658977

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

  15. Aug 2024
    1. Case: Patient Proband SS, Female, Caucasian

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: De novo inheritance, no family history of disease

      CasePresentingHPOs: Hyperammonemia (HP:0001987), oroticaciduria (HP:0003218), Childhood onset (HP:0011463)

      CaseHPOFreeText:

      CaseNOTHPOs: Positive allopurinol test

      CaseNOTHPOFreeText:

      CasePreviousTesting: Genomic DNA isolated from peripheral blood leukocytes or cultured skin fibroblasts. Amplification by PCR used. SSCP analysis performed. Sequencing of both free and immobilized single strands carried out by dideoxy chain termination method.

      SupplementalData: Table 1: Mutations in the Ornithine Transcarbamylase Gene of 17 Females

      Variant: NM_000531.6:c.77+1G>A

      ClinVarID: 97313

      CAID: CA224773

      gnomAD:

    1. Case: Patient #38, Female, Chinese

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: No family history of disease, mutation is inherited

      CasePresentingHPOs: Hyperammonemia (HP:0001987), oroticaciduria (HP:0003218), vomiting (HP:0002013), coma (HP:0001259), lethargy (HP:0001254), seizures (HP:0001250), childhood onset (HP:0011463)

      CaseHPOFreeText: Elevated plasma ammonia at 190 umol/L (Normal: 9-30 umol/L), Elevated urinary orotate at 202 mmol/mmol creatinine (Normal: 0-1.5 mmol/mmol creatinine)

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Normal plasma glutamine at 13.5 umol/L (Normal: 6-30 umol/L), Normal plasma citrulline at 15.75 umol/L (Normal: 7-35 umol/L)

      CasePreviousTesting: gDNA extracted from peripheral blood leukocytes. PCR all coding exons and exon–intron boundaries of the OTC gene using 9 pairs of synthetic oligonucleotide primers, and the primer sequences and annealing temperature. PCR products were then purified and bidirectionally sequenced. The library was sequenced using Illumina HiSeq4000 and generated 150 bp paired-end reads. Data analysis was performed as previously described [Sun Y, Hu G, Liu H, Zhang X, Huang Z, Yan H, et al. Further delineation of the phenotype of truncating KMT2A mutations: the extended Wiedemann–Steiner syndrome. Am J Med Genet A. 2017;173:510–4.]. Multiplex ligation-dependent probe amplification analysis was performed for samples in which Sanger sequencing or WES failed to detect any disease-causing mutation.

      Variant: NM_000531.6:c.67C>T (p.Arg23*)

      ClinVarID: 97292

      CAID: CA224742

      gnomAD:

  16. Jul 2024
    1. Case: patient#5 , female, Italian

      Disease Assertion: UCD/OTCD

      Family Info:

      Case Presenting HPOs: irritability(HP:0000737), lethargy(HP:0001254), vomiting(HP:0002013), Oriticaciduria (HP:0003218), low plasma citrulline (HP:0003572), Elevated circulating alanine aminotransferase concentration(HP:0031964), Elevated circulating aspartate aminotransferase concentration (HP:0031956), childhood onset (HP:0011463)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: Total RNA was isolated from peripheral blood lymphocytes or lymphoblastoid cell lines and from frozen liver biopsy as described in Chomczynski and Sacchi (1987). For each patient two cDNA syntheses were performed: 10mg of total RNA with 800-1000 ng of oligo dT or 500ng of specific primer NR, mapping in the 3’UTR of OTC cDNA Identification of genetic lesions by amplification of the OTC mRNA, expressed in the liver tissue and intestine, from a non-specific tissue like PBL or lymphoblastoid cell lines. Some mutations, particularly those affecting splicing sites, may have a different expression in liver and PBL . In females, including manifesting carriers, this method allows the identification of deletions and gene rearrangements with certainty, but mutations, decreasing mRNA stability, are unlikely to be detected because the normal allele will constitute the majority of the RNA available for RT-PCR and will be preferentially amplified.

      Supplemental Data: Case report section Notes: Hepatomegaly. This mutation, previously reported (Reish et al., 1993), has been correlated with a lethal disease form in a male patient, therefore the mild phenotype in our patient could be explained by a not completely unfavorable X-lyonization

      Variant: NM_000531.6: c.928G>T(p.Glu310*)

      ClinVarID: 97361

      CAID: CA224838

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: 24 yo Laotse patient , female

      Disease Assertion: UCD/OTCD

      Family Info:

      Case Presenting HPOs:Hyperammonemia(HP:0001987), Adult onset (HP:0003581), Elevated circulating alanine aminotransferase concentration(HP:0031964), Elevated circulating aspartate aminotransferase concentration(HP:0031956), oriticaciduria(HP:0003218), Aminoaciduria(HP:0003355, Prolonged prothrombin time(HP:0008151), Cerebral edema(HP:0002181),

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: " Genomic DNA from the patient was isolated from cultivated fibroblasts. Nine pairs of primers were designed from the published sequence of the OTC gene6,7 to allow amplification of all 10 exons including adjacent intron sequences. Single-strand conformational polymorphism analysis of the polymerase chain reaction–amplified individual exon 8 yielded an unusual migration pattern of exon 9

      Supplemental Data: Case report section Notes: Patient had a pregnancy 2 years prior and lost the baby. In this case report, She was a 14weeks pregnant(2nd pregnancy) 24yo . She died during this of severe hyperammonemia 5 days after being administered amino acids through parenteral nutrition. She developed signs of encephalopathy stage 4 with maximal dilated unresponsive pupils, brisk oculocephalic reflex, and severe hyperventilation, requiring mechanical ventilation. MRI revealed revealed diffuse cortical edema with loss of white to gray matter distinction. Increased excretion of Gly, Gln, Ser, Thr, and Lys was found in her urine. Treatment with benzoate was started but didn't save the patient.

      Variant: NM_000531.6: c.892_893del(p.Trp298Aspfs*15)

      ClinVarID: 97348

      CAID: CA224820

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient #11, female, 35yo, slovenian

      Disease Assertion: UCD/OTCD

      Family Info: family history of the disease,

      Case Presenting HPOs: Adult onset(HP:0003581), hyperammonemia(HP:0001987), protein avoidance (HP:0002038)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: Sequencing was performed at a 3rd-party sequencing center using a standardized seq of procedures following PCR-free WGS library preparation protocol Illumina TrueSeq DNA Nano and sequenced on Illumina NovaSeq 6000 platform with a mean autosomal depth greater than 30×. Variants were interpreted by a medical doctor specialized in the NGS sequencing data analysis and those classified as likely pathogenic or pathogenic according to the ACMG/AMP standards and guidelines were considered for reporting, while variants of uncertain clinical significance, were not considered. Likely pathogenic and pathogenic variants were further evaluated by the referring clinical geneticist and were considered and reported if they were classified as both a likely diagnostic finding and if they were compatible with the clinical presentation of referral.

      Supplemental Data: Table 4 and section 3.1(Case description) Notes:

      Variant: NM_000531.6: c.540+265G>A

      ClinVarID: 449382

      CAID: CA658658977

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient #113, Male

      Disease Assertion: UCD/OTCD

      Family Info:

      Case Presenting HPOs: Neonatal onset(HP:0003623), Hyperammonemia HP:0001987

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: GDNA from blood, cultured skin fibroblasts, liver from patients suspected for otc deficiency was used to amplify all 10 exons and exon/intron boundaries using primers listed in Table 1. The amplified DNA fragments were then screened by single-strand conformational polymorphism (SSCP) and the abnormally migrating DNA fragments were sequenced directly from PCR products (w/o subcloning) to identify the mutation. The amino acid residue substitution created by the mutation is examined using an alignment of 26 OTCase sequences from 23 species.

      Supplemental Data: Table 4 Notes:

      Variant: NM_000531.6: c.867+1G>A

      ClinVarID: 97342

      CAID: CA224813

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient #20, Male

      Disease Assertion: UCD/OTCD

      Family Info: NA

      Case Presenting HPOs: Hyperammonemia (HP:0001987), oriticaciduria (HP:0003218), low plasma citrulline (HP:0003572), neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: Genomic DNA was isolated using PUREGENE blood kit from peripheral leukocytes of patients and related family members with informed consents. Amplification by PCR of all 10 exons of the OTC gene was performed using nine pairs of primers designed to span all exons and their adjacent intronic regions. PCR products were subsequently sequenced using ABI3100 Genetic analyzer with BigDye termination ver.3.0.To analyze the activity of OTC protein expressed in the COS-7, high-pressure liquid chromatographic (HPLC) analysis was performed with a Water system, consisting of a model 510 pump and a UV-visible 420 detector.

      Supplemental Data: Table 1 Notes:

      Variant: NM_000531.6: c.796_805del(p.Ile265AspfsX20)

      ClinVarID: NA

      CAID: CA2695233326

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient #1, female Disease Assertion: UCD/OTCD

      Family Info:

      Case Presenting HPOs: Hyperammonemia (HP:0001987), Juvenile onset (HP:0003621)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: "DNA samples were obtained from either peripheral white blood cells or liver biopsies of probands. Patient 1 total liver RNAs were extracted by the acid-phenol-guanidium method and reverse-transcribed in cDNA by hexanucleotide priming using Superscript 11' (Life Technologies, Cergy-Pantoia, France). First strand cDNA was further PCR-amplified using forward and reverse primers specificons 7 and 9 of the OTC gene, respectively. Sequence comparisons were conducted using the FASTA option of the BISANCE package. Secondary protein conformational changes induced by sequence mutations were predicted using the algorithms of the BISANCE package. Nucleotidic changes potentially altering splice sites were studied using the Senapathy's algorithm from the BISANCE package."

      Supplemental Data: TABLE 1, Notes:

      Variant: NM_000531.6: c.731_739del(p.Leu244Profs)

      ClinVarID: 97307

      CAID: CA224765

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient #273, Male

      Disease Assertion: UCD/OTCD

      Family Info: NA

      Case Presenting HPOs: Neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: NA

      Supplemental Data: Supplemental table file Notes:

      Variant: NM_000531.6: c.818del (p.Glu273Glyfs*16)

      ClinVarID: 97338

      CAID: CA224807

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient #5, male, German Disease Assertion: UCD/OTCD

      Family Info: Family history of the disease, Variant found in mother of the patient

      Case Presenting HPOs: infantile onset (HP:0003593), oritic aciduria(HP:0003218), hyperammonemia(HP:0001987), hyperglutaminemia(HP:0003217), low plasma citrulline (HP:0003572)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: Liver tissues were used to extract RNA that was later used to synthesize cDNA. The products were compared to healthy controls in order to detect variants. gDNA, in order to determine the size of deletions in patient 3 and 4 , a set of intronic primers presumably flanking the deletions was used and specific primers allowed sequencing of exactly those critical regions(sequencing on paper). To estimate the relevance of the identified intronic variants in terms of their capability to induce splicing, we used a score developed by Shapiro and Senapathy. This splice score offers information about the usage of a certain splice site

      Supplemental Data: TABLE 1, Notes: died at 11 months, was given medication and low protein diet and was asymptomatic during that time. Died from sever cerebral edema.

      Variant: NM_000531.6: c.1005+1091C>G

      ClinVarID: N/A

      CAID: CA2695233334

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    2. Case: patient #1, male, turkish

      Disease Assertion: UCD/OTCD

      Family Info: Family history of the disease, Variant found in mother of the patient

      Case Presenting HPOs: infantile onset (HP:0003593), coma(HP:0001259), episodic hyperammonemia(HP:0001951), oriticaciduria(HP:0003218)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: Liver tissues were used to extract RNA that was later used to synthesize cDNA. The products were compared to healthy controls in order to detect variants. gDNA, in order to determine the size of deletions in patient 3 and 4 , a set of intronic primers presumably flanking the deletions was used and specific primers allowed sequencing of exactly those critical regions(sequencing on paper). To estimate the relevance of the identified intronic variants in terms of their capability to induce splicing, we used a score developed by Shapiro and Senapathy. This splice score offers information about the usage of a certain splice site

      Supplemental Data: TABLE 1, Notes: very mild movement disorder, the diagnosis was prenatal so measures were taken from birth,. 2 biopsies were performed and the revealed respectively a 30% and 50 % decrease on OTC activity.

      Variant: NM_000531.6: c.867+1126A>G

      ClinVarID: 571311

      CAID: CA891843643

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    3. Case: patient #2, male, Saudi Arabian

      Disease Assertion: UCD/OTCD

      Family Info: Family history of the disease, Variant found in mother of the patient, Brother died of hyperammonemic crisis

      Case Presenting HPOs: intellectual disability (HP:0001249), Neonatal onset (HP:0003623), seizure(HP:0001250), episodic hyperammonemia(HP:0001951), intellectual disability (HP:0001249)

      Case HPO FreeText: hyperammonemic encephalopathy

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: Liver tissues were used to extract RNA that was later used to synthesize cDNA. The products were compared to healthy controls in order to detect variants. gDNA, in order to determine the size of deletions in patient 3 and 4 , a set of intronic primers presumably flanking the deletions was used and specific primers allowed sequencing of exactly those critical regions(sequencing on paper). To estimate the relevance of the identified intronic variants in terms of their capability to induce splicing, we used a score developed by Shapiro and Senapathy. This splice score offers information about the usage of a certain splice site

      Supplemental Data: TABLE 1, Patient was severely mentally retarded after the age of 2. Low OTC activity

      Variant: NM_000531.6: c.540+265G>A(p.Gln180_Glu181insX4)

      ClinVarID: 449382

      CAID: CA658658977

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: no patient ID#, 36yo donor , female

      Disease Assertion: UCD/OTCD

      Family Info:

      Case Presenting HPOs: adult onset (HP:0003581), oriticaciduria (HP:0003218), irritability (HP:0000737), protein avoidance

      Case HPO FreeText: hyperammonemic encephalopathy

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: N/A

      Supplemental Data: TABLE 1, She is vegeterian. The symptoms of OTCD started showing after the patient donated 60% of liver to her sibling. the information reported in this is the biochemical results during hyperammonemic episode following the transplantation. the patient became irritable and confused, and her level of consciousness deteriorated markedly. After hemodialysis the patient recovered.

      Variant: NM_000531.6: c.429T>A(p.Tyr143*)

      ClinVarID: 1072591

      CAID: CA412723166

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: no patient ID#, male

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: Neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: GDNA was extracted from blood or liver tissues using salt and ethanol precipitation. multiplex amplification for exons 1, 5 and 9 to screen male patients with large deletions. Band intensities were measured using a molecular dynamics phosphoimager.

      Supplemental Data: TABLE 2

      Variant: NM_000531.6: c.541-2A>G

      ClinVarID: 97243

      CAID: CA224675

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    2. Case: no patient ID#, male

      Disease Assertion: UCD/OTCD

      Family Info:

      Case Presenting HPOs: Neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: GDNA was extracted from blood or liver tissues using salt and ethanol precipitation. multiplex amplification for exons 1, 5 and 9 to screen male patients with large deletions. Band intensities were measured using a molecular dynamics phosphoimager.

      Supplemental Data: TABLE 2,

      Variant: NM_000531.6: c.437C>G(p.Ser146*)

      ClinVarID: 97201

      CAID: CA224606

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient #573, male

      Disease Assertion: UCD/OTCD

      Family Info:

      Case Presenting HPOs:hyperammonemia (HP:0001987), Neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: GDNA extracted from blood leukocytes using the proteinase K/phenol extraction procedure on a model 340 A nucleic acid extractor (Applied Biosystems). 5mg samples of DNA were digested with BamHI, MspI, or TaqI restriction endonuclease, electrophoresed through 1 % agarose gels, and transferred to a nylon membrane by standard procedures. The blots were then hybridized with a radiolabeled full-length cDNA probe for human OTC.

      Supplemental Data: TABLE 3,

      Variant: NM_000531.6: c.67C>T(p.Arg23*)

      ClinVarID:97292

      CAID: CA224742

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    2. Case: patient SM, male

      Disease Assertion: UCD/OTCD

      Family Info:

      Case Presenting HPOs: Hyperammonemia (HP:0001987), Neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: GDNA extracted from blood leukocytes using the proteinase K/phenol extraction procedure on a model 340 A nucleic acid extractor (Applied Biosystems). 5mg samples of DNA were digested with BamHI, MspI, or TaqI restriction endonuclease, electrophoresed through 1 % agarose gels, and transferred to a nylon membrane by standard procedures. The blots were then hybridized with a radiolabeled full-length cDNA probe for human OTC.

      Supplemental Data: TABLE 3,

      Variant: NM_000531.6: c.274C>T(p.Arg92*)

      ClinVarID:97151

      CAID: CA224530

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient from family 1, male

      Disease Assertion: UCD/OTCD

      Family Info: Family history of the disease

      Case Presenting HPOs: coma(HP:0001259), lethargy(HP:0001254), hyperammonemia (HP:0001987), Neonatal Onset HP:0003623

      Case HPO FreeText: Poor feeding, poor spirit

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: Genomic DNA was extracted using the QIAamp DNA Blood Midi Kit (Qiagen, Duesseldorf, Germany). Quality control assessment of DNA samples was performed using the NanoDrop 2000 ultra-microvolume nucleic acid and protein spectrophotometer (Thermo, Waltham, MA, USA). The purity of DNA was required to be between 1.8 and 2.0.

      Supplemental Data: TABLE 1, admitted to neonatal department because of poor feeding, poor spirit, coma, and lethargy. The maternal grandmother of the proband in this family had given birth to 3 boys and 2 girls. Two boys died within 1 month after birth

      Variant: NM_000531.6: c.867+1G>C

      ClinVarID:N/A

      CAID: CA412723994

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient #5, female

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: Neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: gDNA testing involves PCR amplification of all 10 exons and exon/intron boundaries followed by screening for mutations or sequencing of all fragments, For these patients, confirmation of the diagnosis requires enzymatic assays. No specifications about the test

      Supplemental Data: TABLE 1

      Variant: NM_000531.6: c.53del (p.His18Profs*20)

      ClinVarID: 97239

      CAID: CA224671

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    2. Case: patient #85, female

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs:

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: gDNA testing involves PCR amplification of all 10 exons and exon/intron boundaries followed by screening for mutations or sequencing of all fragments, For these patients, confirmation of the diagnosis requires enzymatic assays. No specifications about the test

      Supplemental Data: TABLE 1

      Variant: NM_000531.6: c.449_451del(p.Leu151Trpfs*36)

      ClinVarID: N/A

      CAID: CA2759533410

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    3. Case: patient #154, male

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: Neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: gDNA testing involves PCR amplification of all 10 exons and exon/intron boundaries followed by screening for mutations or sequencing of all fragments, For these patients, confirmation of the diagnosis requires enzymatic assays. No specifications about the test

      Supplemental Data: TABLE 1

      Variant: NM_000531.6: c.664-1G>A

      ClinVarID: 97288

      CAID: CA224811

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    4. Case: patient #188, male

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: Neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: gDNA testing involves PCR amplification of all 10 exons and exon/intron boundaries followed by screening for mutations or sequencing of all fragments, For these patients, confirmation of the diagnosis requires enzymatic assays. No specifications about the test

      Supplemental Data: TABLE 1

      Variant: NM_000531.6: c.835C>T(p.Gln279*)

      ClinVarID: 97341

      CAID: CA224811

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    5. Case: patient #213, male

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: Neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: gDNA testing involves PCR amplification of all 10 exons and exon/intron boundaries followed by screening for mutations or sequencing of all fragments, For these patients, confirmation of the diagnosis requires enzymatic assays. No specifications about the test

      Supplemental Data: TABLE 1

      Variant: NM_000531.6: c.962C>A(p.Ser321*)

      ClinVarID: 97373

      CAID: CA224859

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    6. Case: patient #220, male

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: Neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: gDNA testing involves PCR amplification of all 10 exons and exon/intron boundaries followed by screening for mutations or sequencing of all fragments, For these patients, confirmation of the diagnosis requires enzymatic assays. No specifications about the test

      Supplemental Data: Table 1

      Variant: NM_000531.6: c.1005+2T>C

      ClinVarID: 97090

      CAID: CA224431

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient #335, female

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs:

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: No specific functional tests indicated

      Supplemental Data: In supplemental data files

      Variant: NM_000531.6: c.861_862insAC (p.Met288Thrfs*2)

      ClinVarID: N/A

      CAID: CA2759522140

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    2. Case: patient #303, female

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs:

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: No specific functional tests indicated

      Supplemental Data: In supplemental data files

      Variant: NM_000531.6: c.766G>T(p.256Gly*)

      ClinVarID: 870326

      CAID: CA412722685

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    3. Case: patient #212, female

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs:

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: No specific functional tests indicated

      Supplemental Data: In supplemental data files

      Variant: NM_000531.6:c.561delA(p.Gly188Valfs*18)

      ClinVarID: N/A

      CAID: CA2499307429

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    4. Case: patient #198, male

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: Neonatal onset (HP:0003623)

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: No specific functional tests indicated

      Supplemental Data: In supplemental data files

      Variant: NM_000531.6:c.538C>T(p.Gln180*)

      ClinVarID: N/A

      CAID: CA412724187

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient #16, female, Japanese

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs:

      Case HPO FreeText:

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: The severity of missense mutations was assessed using conservation and solvent accessible area of the replaced amino acid, calculated destabilization of mutant proteins and their SIFT and PolyPhen2 scores

      Supplemental Data: Kido_et_al_2022_fgene_Data Sheet 2

      Variant: NM_000531.6:c.77+1G>T

      ClinVarID: 97314

      CAID: CA224774

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: patient #55, male, Japanese

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: Seizure (HP:0001250), Hyperammonemia (HP:0001987), Intellectual disability (HP:0001249)

      Case HPO FreeText: abnormal brain MRI and brain waves, acute liver failure, corneal opacity

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: The mRNA ref seq were, wherein the “A” nucleotide of the start codon ATG constituted as +1 numbering of the cDNA sequence. Met encoded by the start codon ATG also represented +1 for the amino acid numbering as set forth by the preprotein seq. PolyPhen-2, SIFT, and I-Mutant 3 tools were used for predicting the potential impact of an amino acid alteration in missense mutations on the function of each enzyme.

      Supplemental Data: Table 1

      Variant: NM_000531.6:c.c.929_931del(p.Glu310Valfs*45)

      ClinVarID: 858012

      CAID: CA916083888

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    2. Case: patient #56, female, Japanese

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: ,Hyperammonemia (HP:0001987)

      Case HPO FreeText: N/A

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: The mRNA ref seq were, wherein the “A” nucleotide of the start codon ATG constituted as +1 numbering of the cDNA sequence. Met encoded by the start codon ATG also represented +1 for the amino acid numbering as set forth by the preprotein seq. PolyPhen-2, SIFT, and I-Mutant 3 tools were used for predicting the potential impact of an amino acid alteration in missense mutations on the function of each enzyme.

      Supplemental Data: Table 1, patient had a liver transplant at 12yo.

      Variant: NM_000531.6:c.940G>T(p.Glu314*)

      ClinVarID: N/A

      CAID: CA412726302

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    3. Case: patient #52, female, Japanese

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: ,Hyperammonemia (HP:0001987)

      Case HPO FreeText: N/A

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: The mRNA ref seq were, wherein the “A” nucleotide of the start codon ATG constituted as +1 numbering of the cDNA sequence. Met encoded by the start codon ATG also represented +1 for the amino acid numbering as set forth by the preprotein seq. PolyPhen-2, SIFT, and I-Mutant 3 tools were used for predicting the potential impact of an amino acid alteration in missense mutations on the function of each enzyme.

      Supplemental Data: Table 1

      Variant: NM_000531.6:c.894G>A(p.Trp298*)

      ClinVarID: N/A

      CAID: CA412725724

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    4. Case: patient #51, male, Japanese

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: neonatal(HP:0003623), intellectual disability (HP:0001249), seizure (HP:0001250),Hyperammonemia (HP:0001987)

      Case HPO FreeText: Hypertonus, Autism, Acute liver failure. very high blood ammonia

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: The mRNA ref seq were, wherein the “A” nucleotide of the start codon ATG constituted as +1 numbering of the cDNA sequence. Met encoded by the start codon ATG also represented +1 for the amino acid numbering as set forth by the preprotein seq. PolyPhen-2, SIFT, and I-Mutant 3 tools were used for predicting the potential impact of an amino acid alteration in missense mutations on the function of each enzyme.

      Supplemental Data: Table 1

      Variant: NM_000531.6:c.867+1G>C

      ClinVarID: N/A

      CAID: CA412723994

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    5. Case: patient #50, male, Japanese

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: Seizure HP:0001250, hyperammonemia HP: 0001987

      Case HPO FreeText: Hepatomegaly, Abnormal brain MRI and brain waves, Acute liver failure, Corneal opacity

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: The mRNA ref seq were, wherein the “A” nucleotide of the start codon ATG constituted as +1 numbering of the cDNA sequence. Met encoded by the start codon ATG also represented +1 for the amino acid numbering as set forth by the preprotein seq. PolyPhen-2, SIFT, and I-Mutant 3 tools were used for predicting the potential impact of an amino acid alteration in missense mutations on the function of each enzyme.

      Supplemental Data: Table 1

      Variant: NM_000531.6:c.834_840del(p.Gln279Serfs*8)

      ClinVarID: N/A

      CAID: CA2695233329

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: no patient ID, Female

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: HP:0001951, HP: 0001987

      Case HPO FreeText: episodic hyperammonemia, hyperammonemia

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: "Genomic DNAs were extracted from leukocytes, The ten exons and intron-exon boundaries of the OTC gene were PCR amplified and analyzed by Sanger sequencing on an ABI3100 sequencer. Intragenic deletions/duplications were searched for by Multiple Ligation Probe Dependent Amplification assay. Potential impact of non truncating variants on mRNA and protein was predicted using Splice Site Prediction. OTC variants were split into two groups, “severe” and “mild,” based on their impact on the clinical phenotype and on the OTC protein.

      Supplemental Data: Table 3, All nuclear family members were tested but no information about their genotype. the condition to be part of this study was the presence of at least one heterozygous female in the pedigree of the patient.

      Variant: NM_000531.6:c.1052delA(p.Lys351Serfs*44)

      ClinVarID: 915468

      CAID: CA1139667400

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    2. Case: no patient ID, Female

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: HP:0003623, HP: 0001987

      Case HPO FreeText: Neonatal onset, hyperammonemia

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: "Genomic DNAs were extracted from leukocytes, The ten exons and intron-exon boundaries of the OTC gene were PCR amplified and analyzed by Sanger sequencing on an ABI3100 sequencer. Intragenic deletions/duplications were searched for by Multiple Ligation Probe Dependent Amplification assay. Potential impact of non truncating variants on mRNA and protein was predicted using Splice Site Prediction. OTC variants were split into two groups, “severe” and “mild,” based on their impact on the clinical phenotype and on the OTC protein.

      Supplemental Data: Table 3, All nuclear family members were tested but no information about their genotype. the condition to be part of this study was the presence of at least one heterozygous female in the pedigree of the patient.

      Variant: NM_000531.6:c.766G>T(p.Gly256*)

      ClinVarID: 870326

      CAID: CA412722685

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    3. Case: no patient ID, Female

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: HP:0001951, HP: 0001987

      Case HPO FreeText: episodic hyperammonemia, hyperammonemia

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: "Genomic DNAs were extracted from leukocytes, The ten exons and intron-exon boundaries of the OTC gene were PCR amplified and analyzed by Sanger sequencing on an ABI3100 sequencer. Intragenic deletions/duplications were searched for by Multiple Ligation Probe Dependent Amplification assay. Potential impact of non truncating variants on mRNA and protein was predicted using Splice Site Prediction. OTC variants were split into two groups, “severe” and “mild,” based on their impact on the clinical phenotype and on the OTC protein.

      Supplemental Data: Table 3, All nuclear family members were tested but no information about their genotype. the condition to be part of this study was the presence of at least one heterozygous female in the pedigree of the patient.

      Variant: NM_000531.6:c.568dupA(p.Thr190Asnfs*35)

      ClinVarID: 870328

      CAID: CA916083887

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    4. Case: no patient ID, male

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: HP:0003623, HP: 0001987

      Case HPO FreeText: Neonatal onset, hyperammonemia

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: "Genomic DNAs were extracted from leukocytes, The ten exons and intron-exon boundaries of the OTC gene were PCR amplified and analyzed by Sanger sequencing on an ABI3100 sequencer. Intragenic deletions/duplications were searched for by Multiple Ligation Probe Dependent Amplification assay. Potential impact of non truncating variants on mRNA and protein was predicted using Splice Site Prediction. OTC variants were split into two groups, “severe” and “mild,” based on their impact on the clinical phenotype and on the OTC protein.

      Supplemental Data: Table 3, All nuclear family members were tested but no information about their genotype. the condition to be part of this study was the presence of at least one heterozygous female in the pedigree of the patient.

      Variant: NM_000531.6:c.217-2A>G(IVS2)

      ClinVarID: 915470

      CAID: CA412716751

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    1. Case: Patient #27, male, Korean

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: HP:0003593, HP:0003218, HP: 0001987

      Case HPO FreeText: Infantile onset, oroticaciduria, hyperammonemia

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: "Potential impact of mutations on OTC function and/or folding assessed by multiple alignments of orthologous protein sequences and human OTC and structural data from Protein Data Bank (1C9Y and available orthologs). In M patients, the approximate extent of the deletions assessed by inspection of presence/absence of PCR products. In F patients, the deletions determined by the SALSA multiplex ligation probe amplification (MLPA) KIT P079 OTC (MRC-Holland, Amsterdam, the Netherlands) and the Affymetrix Human SNP 6.0 array (Santa Clara, CA). Sequence spanning 38,211,736 – 38,300,703 bp region on chromosome X (GRCh37) and including OTC was scanned for motifs CCTCCCT, CCTCCTT, CCTCCCTT, CCCCACCCC, CCNCCNTNNCCNC, GGNGGNAGGG and their complements known as being associated with recombination hotspots. Repeats capable of non-B DNA structure formation implicated in double strand breaks (DSBs) were sought by complexity analysis . X-inactivation ratio determined by analysis of methylation status of the human androgen-receptor locus (HUMARA)

      Supplemental Data: Table 1&2, The minimum plasma ammonia, orotic acid and Gln+Glu concentrations depends on certain age range: Plasma ammonia: neonates <90μmol/l, other <60μmol/l. Urinary orotic acid: 0–1year <6.6mmol/mol creatinine, 1 – 10 years <3.5 mmol/mol creatinine, over 10 years <2.4 mmol/mol creatinine. Serum glutamate + glutamine: 0 – 1 month 200–1200μmol/l, 1 month–1year 200–1100μmol/l, 1year–18years 200–900μmol/l, over 18years 200–800μmol/l.

      Variant: NM_000531.6:c.929_931del(p.Glu310Valfs*45)

      ClinVarID: N/A

      CAID: CA916083888

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    2. Case: Patient #37, female, Korean

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: HP:0011463, HP:0003218, HP: 0001987

      Case HPO FreeText: Childhood onset, oroticaciduria, hyperammonemia

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: "Potential impact of mutations on OTC function and/or folding assessed by multiple alignments of orthologous protein sequences and human OTC and structural data from Protein Data Bank (1C9Y and available orthologs). In M patients, the approximate extent of the deletions assessed by inspection of presence/absence of PCR products. In F patients, the deletions determined by the SALSA multiplex ligation probe amplification (MLPA) KIT P079 OTC (MRC-Holland, Amsterdam, the Netherlands) and the Affymetrix Human SNP 6.0 array (Santa Clara, CA). Sequence spanning 38,211,736 – 38,300,703 bp region on chromosome X (GRCh37) and including OTC was scanned for motifs CCTCCCT, CCTCCTT, CCTCCCTT, CCCCACCCC, CCNCCNTNNCCNC, GGNGGNAGGG and their complements known as being associated with recombination hotspots. Repeats capable of non-B DNA structure formation implicated in double strand breaks (DSBs) were sought by complexity analysis . X-inactivation ratio determined by analysis of methylation status of the human androgen-receptor locus (HUMARA)

      Supplemental Data: Table 1&2, The minimum plasma ammonia, orotic acid and Gln+Glu concentrations depends on certain age range: Plasma ammonia: neonates <90μmol/l, other <60μmol/l. Urinary orotic acid: 0–1year <6.6mmol/mol creatinine, 1 – 10 years <3.5 mmol/mol creatinine, over 10 years <2.4 mmol/mol creatinine. Serum glutamate + glutamine: 0 – 1 month 200–1200μmol/l, 1 month–1year 200–1100μmol/l, 1year–18years 200–900μmol/l, over 18years 200–800μmol/l.

      Variant: NM_000531.6:c.1043delA(p.Gln348Argfs*47)

      ClinVarID: N/A

      CAID: CA2695233335

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    3. Case: Patient #35, female, Korean

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: HP:0011463, HP:0003218, HP: 0001987

      Case HPO FreeText: childhood onset, oroticaciduria, hyperammonemia

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: "Potential impact of mutations on OTC function and/or folding assessed by multiple alignments of orthologous protein sequences and human OTC and structural data from Protein Data Bank (1C9Y and available orthologs). In M patients, the approximate extent of the deletions assessed by inspection of presence/absence of PCR products. In F patients, the deletions determined by the SALSA multiplex ligation probe amplification (MLPA) KIT P079 OTC (MRC-Holland, Amsterdam, the Netherlands) and the Affymetrix Human SNP 6.0 array (Santa Clara, CA). Sequence spanning 38,211,736 – 38,300,703 bp region on chromosome X (GRCh37) and including OTC was scanned for motifs CCTCCCT, CCTCCTT, CCTCCCTT, CCCCACCCC, CCNCCNTNNCCNC, GGNGGNAGGG and their complements known as being associated with recombination hotspots. Repeats capable of non-B DNA structure formation implicated in double strand breaks (DSBs) were sought by complexity analysis . X-inactivation ratio determined by analysis of methylation status of the human androgen-receptor locus (HUMARA)

      Supplemental Data: Table 1&2, This is a large deletion. The minimum plasma ammonia, orotic acid and Gln+Glu concentrations depends on certain age range: Plasma ammonia: neonates <90μmol/l, other <60μmol/l. Urinary orotic acid: 0–1year <6.6mmol/mol creatinine, 1 – 10 years <3.5 mmol/mol creatinine, over 10 years <2.4 mmol/mol creatinine. Serum glutamate + glutamine: 0 – 1 month 200–1200μmol/l, 1 month–1year 200–1100μmol/l, 1year–18years 200–900μmol/l, over 18years 200–800μmol/l.

      Variant: NM_000531.6:c.853C>T(p.Gln285*)

      ClinVarID: N/A

      CAID: CA412723777

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    4. Case: Patient #34, female, Korean

      Disease Assertion: UCD/OTCD

      Family Info: N/A

      Case Presenting HPOs: HP:0011463, HP:0003218, HP: 0001987

      Case HPO FreeText: childhood onset, oroticaciduria, hyperammonemia

      Case NOT HPOs:

      Case NOT HPO Free Text:

      Case Previous Testing: "Potential impact of mutations on OTC function and/or folding assessed by multiple alignments of orthologous protein sequences and human OTC and structural data from Protein Data Bank (1C9Y and available orthologs). In M patients, the approximate extent of the deletions assessed by inspection of presence/absence of PCR products. In F patients, the deletions determined by the SALSA multiplex ligation probe amplification (MLPA) KIT P079 OTC (MRC-Holland, Amsterdam, the Netherlands) and the Affymetrix Human SNP 6.0 array (Santa Clara, CA). Sequence spanning 38,211,736 – 38,300,703 bp region on chromosome X (GRCh37) and including OTC was scanned for motifs CCTCCCT, CCTCCTT, CCTCCCTT, CCCCACCCC, CCNCCNTNNCCNC, GGNGGNAGGG and their complements known as being associated with recombination hotspots. Repeats capable of non-B DNA structure formation implicated in double strand breaks (DSBs) were sought by complexity analysis . X-inactivation ratio determined by analysis of methylation status of the human androgen-receptor locus (HUMARA)

      Supplemental Data: Table 1&2, This is a manifesting heterozygote. Serum Gln+Glu was considered elevated. The minimum plasma ammonia, orotic acid and Gln+Glu concentrations depends on certain age range: Plasma ammonia: neonates <90μmol/l, other <60μmol/l. Urinary orotic acid: 0–1year <6.6mmol/mol creatinine, 1 – 10 years <3.5 mmol/mol creatinine, over 10 years <2.4 mmol/mol creatinine. Serum glutamate + glutamine: 0 – 1 month 200–1200μmol/l, 1 month–1year 200–1100μmol/l, 1year–18years 200–900μmol/l, over 18years 200–800μmol/l.

      Variant: NM_000531.6:c.717+1G>T(IVS7+1G>T)

      ClinVarID: 97298

      CAID: CA224753

      gnomAD:

      Gene Name: OTC (ornithine transcarbamylase)

    5. Case: Patient #30, female, Korean

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0011463, HP:0003218

      CaseHPOFreeText: childhood onset, oroticaciduria,

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: "Potential impact of mutations on OTC function and/or folding assessed by multiple alignments of orthologous protein sequences and human OTC and structural data from Protein Data Bank (1C9Y and available orthologs). In M patients, the approximate extent of the deletions assessed by inspection of presence/absence of PCR products. In F patients, the deletions determined by the SALSA multiplex ligation probe amplification (MLPA) KIT P079 OTC (MRC-Holland, Amsterdam, the Netherlands) and the Affymetrix Human SNP 6.0 array (Santa Clara, CA). Sequence spanning 38,211,736 – 38,300,703 bp region on chromosome X (GRCh37) and including OTC was scanned for motifs CCTCCCT, CCTCCTT, CCTCCCTT, CCCCACCCC, CCNCCNTNNCCNC, GGNGGNAGGG and their complements known as being associated with recombination hotspots. Repeats capable of non-B DNA structure formation implicated in double strand breaks (DSBs) were sought by complexity analysis . X-inactivation ratio determined by analysis of methylation status of the human androgen-receptor locus (HUMARA)

      Supplemental Data: Table 1&2, Serum Gln+Glu was considered elevated, the minimum plasma ammonia, orotic acid and Gln+Glu concentrations depends on certain age range: Plasma ammonia: neonates <90μmol/l, other <60μmol/l. Urinary orotic acid: 0–1year <6.6mmol/mol creatinine, 1 – 10 years <3.5 mmol/mol creatinine, over 10 years <2.4 mmol/mol creatinine. Serum glutamate + glutamine: 0 – 1 month 200–1200μmol/l, 1 month–1year 200–1100μmol/l, 1year–18years 200–900μmol/l, over 18years 200–800μmol/l.

      Variant: NM_000531.6:c.491C>G(p.Ser164*)

      ClinVarID: 97220

      CAID: CA224642

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    6. Case: Patient #6, male, Korean

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0011463, HP:0001987, HP:0003218

      CaseHPOFreeText: Neonatal onset, hyperammonemia, oroticaciduria,

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: "Potential impact of mutations on OTC function and/or folding assessed by multiple alignments of orthologous protein sequences and human OTC and structural data from Protein Data Bank (1C9Y and available orthologs). In M patients, the approximate extent of the deletions assessed by inspection of presence/absence of PCR products. In F patients, the deletions determined by the SALSA multiplex ligation probe amplification (MLPA) KIT P079 OTC (MRC-Holland, Amsterdam, the Netherlands) and the Affymetrix Human SNP 6.0 array (Santa Clara, CA). Sequence spanning 38,211,736 – 38,300,703 bp region on chromosome X (GRCh37) and including OTC was scanned for motifs CCTCCCT, CCTCCTT, CCTCCCTT, CCCCACCCC, CCNCCNTNNCCNC, GGNGGNAGGG and their complements known as being associated with recombination hotspots. Repeats capable of non-B DNA structure formation implicated in double strand breaks (DSBs) were sought by complexity analysis . X-inactivation ratio determined by analysis of methylation status of the human androgen-receptor locus (HUMARA)

      Supplemental Data: Table 1&2, the minimum plasma ammonia, orotic acid and Gln+Glu concentrations depends on certain age range: Plasma ammonia: neonates <90μmol/l, other <60μmol/l. Urinary orotic acid: 0–1year <6.6mmol/mol creatinine, 1 – 10 years <3.5 mmol/mol creatinine, over 10 years <2.4 mmol/mol creatinine. Serum glutamate + glutamine: 0 – 1 month 200–1200μmol/l, 1 month–1year 200–1100μmol/l, 1year–18years 200–900μmol/l, over 18years 200–800μmol/l.

      Variant: NM_000531.6:c.461_471del(p.Glu154Alafs*18)

      ClinVarID: N/A

      CAID:CA2695233305

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    1. Case: Patient #15, male, Korean

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0011463, HP:0001987, HP:0003218, HP:0003572

      CaseHPOFreeText: Neonatal onset, hyperammonemia, oroticaciduria, low plasma citrulline

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: Genomic DNA was extracted from peripheral blood leukocytes. A total of 10 coding exons and exon–intron boundaries of the OTC gene were amplified by PCR with customized primers. PCR products were directly sequenced with the same primers . Sequencing results were compared with the established human OTC sequences(NM_000531.5). Multiplex ligation-dependent probe amplification analysis was performed for patients in whom no OTC mutations were identified by direct sequencing using the OTC MLPA kit.

      Supplemental Data: Table 1, mother is a carrier, no range was given for blood ammonia concentration, range given in the tables for glutamine and urine orotate is slightly different than the one in the results paragraphs.

      Variant: NM_000531.6:c.796_805del(p.Ile265_Gly268delinsAspfs*19)

      ClinVarID: N/A

      CAID:CA2695233326

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    2. Case: Patient #45, female, Korean

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: variant in mother (father not tested) and brother

      CasePresentingHPOs: HP:0003593, HP:0001987, HP:0003218

      CaseHPOFreeText: infantile onset, hyperammonemia, oroticaciduria

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: Genomic DNA was extracted from peripheral blood leukocytes. A total of 10 coding exons and exon–intron boundaries of the OTC gene were amplified by PCR with customized primers. PCR products were directly sequenced with the same primers . Sequencing results were compared with the established human OTC sequences(NM_000531.5). Multiplex ligation-dependent probe amplification analysis was performed for patients in whom no OTC mutations were identified by direct sequencing using the OTC MLPA kit.

      Supplemental Data: Table 1, mother is a carrier, the mutation was also found in patient 13(her brother), no range was given for blood ammonia concentration, range given in the tables for glutamine and urine orotate is slightly different than the one in the results paragraphs.

      Variant: NM_000531.6c.664_667delinsAC(p.Gly222Thrfs*2)

      ClinVarID: N/A

      CAID:CA2695233319

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    3. Case: Patient #42, female, Korean

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0011463, HP:0001987, HP:0003218

      CaseHPOFreeText: Childhood onset, hyperammonemia, oroticaciduria

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: Genomic DNA was extracted from peripheral blood leukocytes. A total of 10 coding exons and exon–intron boundaries of the OTC gene were amplified by PCR with customized primers. PCR products were directly sequenced with the same primers . Sequencing results were compared with the established human OTC sequences(NM_000531.5). Multiplex ligation-dependent probe amplification analysis was performed for patients in whom no OTC mutations were identified by direct sequencing using the OTC MLPA kit.

      Supplemental Data: Table 1, no range was given for blood ammonia concentration, range given in the tables for glutamine and urine orotate is slightly different than the one in the results paragraphs.

      Variant: NM_000531.6:c.958C>T(p.Arg320*)

      ClinVarID: 97371

      CAID:CA285809

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    4. Case: Patient #44, female, Korean

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: variant in mother (father not tested)

      CasePresentingHPOs: HP:0011463, HP:0001987, HP:0003218, HP:0003217

      CaseHPOFreeText: Childhood onset, hyperammonemia, oroticaciduria, hyperglutaminemia

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: Genomic DNA was extracted from peripheral blood leukocytes. A total of 10 coding exons and exon–intron boundaries of the OTC gene were amplified by PCR with customized primers. PCR products were directly sequenced with the same primers . Sequencing results were compared with the established human OTC sequences(NM_000531.5). Multiplex ligation-dependent probe amplification analysis was performed for patients in whom no OTC mutations were identified by direct sequencing using the OTC MLPA kit.

      Supplemental Data: Table 1, mother is a carrier, no range was given for blood ammonia concentration, range given in the tables for glutamine and urine orotate is slightly different than the one in the results paragraphs.

      Variant: NM_000531.6:c.799_800insA (p.Ser267Lysfs*26)

      ClinVarID: N/A

      CAID:CA2695233327

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    1. Case: Patient #30, male, Chinese

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: no family history of the disease

      CasePresentingHPOs: HP:0003593, HP:0001987, HP:0003218

      CaseHPOFreeText: infantile onset, hyperammonemia, oroticaciduria

      CaseNOTHPOs:

      CaseNOTHPOFreeText: No neurological damage

      CasePreviousTesting: gDNA extracted from peripheral blood leukocytes. PCR all coding exons and exon–intron boundaries of the OTC gene using 9 pairs of synthetic oligonucleotide primers, and the primer sequences and annealing temperature. PCR products were then purified and bidirectionally sequenced. The library was sequenced using Illumina HiSeq4000 and generated 150 bp paired-end reads. Data analysis was performed as previously described [Sun Y, Hu G, Liu H, Zhang X, Huang Z, Yan H, et al. Further delineation of the phenotype of truncating KMT2A mutations: the extended Wiedemann–Steiner syndrome. Am J Med Genet A. 2017;173:510–4.]. Multiplex ligation-dependent probe amplification analysis was performed for samples in which Sanger sequencing or WES failed to detect any disease-causing mutation.

      SupplementalData: Table 3, drug treatment(L-arginine, L-Citrulline, sodium benzoate, and sodium phenylbutyrate)

      Variant: NM_000531.6:c.929_931del(p.Glu310Valfs*45)

      ClinVarID: 858012

      CAID:CA916083888

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    2. Case: Patient #61, female, Chinese

      DiseaseAssertion: UCD/OTCD

      FamilyInfo:

      CasePresentingHPOs: HP:0011463, HP:0001987, HP:0003218, HP:0003572

      CaseHPOFreeText: childhood onset, hyperammonemia, oroticaciduria, low plasma citrulline

      CaseNOTHPOs:

      CaseNOTHPOFreeText: neurological damage

      CasePreviousTesting: gDNA extracted from peripheral blood leukocytes. PCR all coding exons and exon–intron boundaries of the OTC gene using 9 pairs of synthetic oligonucleotide primers, and the primer sequences and annealing temperature. PCR products were then purified and bidirectionally sequenced. The library was sequenced using Illumina HiSeq4000 and generated 150 bp paired-end reads. Data analysis was performed as previously described [Sun Y, Hu G, Liu H, Zhang X, Huang Z, Yan H, et al. Further delineation of the phenotype of truncating KMT2A mutations: the extended Wiedemann–Steiner syndrome. Am J Med Genet A. 2017;173:510–4.]. Multiplex ligation-dependent probe amplification analysis was performed for samples in which Sanger sequencing or WES failed to detect any disease-causing mutation.

      SupplementalData: Table 3, drug treatment(L-arginine, L-Citrulline, sodium benzoate, and sodium phenylbutyrate)

      Variant: NM_000531.6:c.868-1G>C

      ClinVarID: N/A

      CAID:CA412725475

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    3. Case: Patient #52, female, Chinese

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: family history of the disease, variant in probands mother and father

      CasePresentingHPOs: HP:0011463, HP:0001987, HP:0003218, HP:0003572

      CaseHPOFreeText: childhood onset,, hyperammonemia, oroticaciduria, low plasma citrulline

      CaseNOTHPOs:

      CaseNOTHPOFreeText: neurological damage

      CasePreviousTesting: gDNA extracted from peripheral blood leukocytes. PCR all coding exons and exon–intron boundaries of the OTC gene using 9 pairs of synthetic oligonucleotide primers, and the primer sequences and annealing temperature. PCR products were then purified and bidirectionally sequenced. The library was sequenced using Illumina HiSeq4000 and generated 150 bp paired-end reads. Data analysis was performed as previously described [Sun Y, Hu G, Liu H, Zhang X, Huang Z, Yan H, et al. Further delineation of the phenotype of truncating KMT2A mutations: the extended Wiedemann–Steiner syndrome. Am J Med Genet A. 2017;173:510–4.]. Multiplex ligation-dependent probe amplification analysis was performed for samples in which Sanger sequencing or WES failed to detect any disease-causing mutation.

      SupplementalData: Table 3, inherited mutation, drug treatment(L-arginine, L-Citrulline, sodium benzoate, and sodium phenylbutyrate), low protein diet treatment, and continuous veno venous hemodialfiltration

      Variant: NM_000531.6:c.703C>T

      ClinVarID: N/A

      CAID: CA412721652

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    4. Case: Patient #20, male, Chinese

      DiseaseAssertion: UCD/OTCD

      FamilyInfo:

      CasePresentingHPOs: HP:0011463, HP:0001987, HP:0003218

      CaseHPOFreeText: childhood onset, hyperammonemia, oroticaciduria

      CaseNOTHPOs:

      CaseNOTHPOFreeText: No neurological damage

      CasePreviousTesting: gDNA extracted from peripheral blood leukocytes. PCR all coding exons and exon–intron boundaries of the OTC gene using 9 pairs of synthetic oligonucleotide primers, and the primer sequences and annealing temperature. PCR products were then purified and bidirectionally sequenced. The library was sequenced using Illumina HiSeq4000 and generated 150 bp paired-end reads. Data analysis was performed as previously described [Sun Y, Hu G, Liu H, Zhang X, Huang Z, Yan H, et al. Further delineation of the phenotype of truncating KMT2A mutations: the extended Wiedemann–Steiner syndrome. Am J Med Genet A. 2017;173:510–4.]. Multiplex ligation-dependent probe amplification analysis was performed for samples in which Sanger sequencing or WES failed to detect any disease-causing mutation.

      SupplementalData: Table 3, drug treatment (L-arginine, L-Citrulline, sodium benzoate, and sodium phenylbutyrate), deceased

      Variant: NM_000531.6:c.794G>A(p.Trp265*)

      ClinVarID: N/A

      CAID:CA412722994

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    5. Case: Patient #60, female, Chinese

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: family history of the disease

      CasePresentingHPOs: HP:0011463, HP:0001987, HP:0003218, HP:0003572

      CaseHPOFreeText: childhood onset,, hyperammonemia, oroticaciduria, low plasma citrulline

      CaseNOTHPOs:

      CaseNOTHPOFreeText: neurological damage

      CasePreviousTesting: gDNA extracted from peripheral blood leukocytes. PCR all coding exons and exon–intron boundaries of the OTC gene using 9 pairs of synthetic oligonucleotide primers, and the primer sequences and annealing temperature. PCR products were then purified and bidirectionally sequenced. The library was sequenced using Illumina HiSeq4000 and generated 150 bp paired-end reads. Data analysis was performed as previously described [Sun Y, Hu G, Liu H, Zhang X, Huang Z, Yan H, et al. Further delineation of the phenotype of truncating KMT2A mutations: the extended Wiedemann–Steiner syndrome. Am J Med Genet A. 2017;173:510–4.]. Multiplex ligation-dependent probe amplification analysis was performed for samples in which Sanger sequencing or WES failed to detect any disease-causing mutation.

      SupplementalData: Table 3, inherited mutation, drug treatment(L-arginine, L-Citrulline, sodium benzoate, and sodium phenylbutyrate), low protein diet treatment, and continuous veno venous hemodialfiltration

      Variant: NM_000531.6:c.718-1G>A

      ClinVarID: N/A

      CAID: CA412722112

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    6. Case: Patient #58, female, Chinese

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: variant pin proband's mother and father CasePresentingHPOs: HP:0003593, HP:0002038, HP:0001987, HP:0003218, HP:0003572

      CaseHPOFreeText: infantile onset , protein avoidance, hyperammonemia, oroticaciduria, low plasma citrulline

      CaseNOTHPOs: N/A

      CaseNOTHPOFreeText: neurological damage

      CasePreviousTesting: gDNA extracted from peripheral blood leukocytes. PCR all coding exons and exon–intron boundaries of the OTC gene using 9 pairs of synthetic oligonucleotide primers, and the primer sequences and annealing temperature. PCR products were then purifed and bidirectionally sequenced. The library was sequenced using Illumina HiSeq4000 and generated 150 bp paired-end reads. Data analysis was performed as previously described [Sun Y, Hu G, Liu H, Zhang X, Huang Z, Yan H, et al. Further delineation of the phenotype of truncating KMT2A mutations: the extended Wiedemann–Steiner syndrome. Am J Med Genet A. 2017;173:510–4.]. Multiplex ligation-dependent probe amplifcation analysis was performed for samples in which Sanger sequencing or WES failed to detect any disease-causing mutation.

      SupplementalData: Table 3, low protein diet treatment and drug treatment(L-arginine, L-Citrulline, sodium benzoate, and sodium phenylbutyrate), neurological damage

      Variant: NM_000531.6:c.540+265G>A

      ClinVarID: 449382

      CAID: CA658658977

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    7. Case: Patient #3, male, Chinese

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: Family history of the disease, variant in probands mother and father

      CasePresentingHPOs: HP:0003623, HP:0001987, HP:0003218

      CaseHPOFreeText: neonatal, hyperammonemia , oroticaciduria

      CaseNOTHPOs: N/A

      CaseNOTHPOFreeText: No neurological damage

      CasePreviousTesting: gDNA extracted from peripheral blood leukocytes. PCR all coding exons and exon–intron boundaries of the OTC gene using 9 pairs of synthetic oligonucleotide primers, and the primer sequences and annealing temperature. PCR products were then purified and bidirectionally sequenced. The library was sequenced using Illumina HiSeq4000 and generated 150 bp paired-end reads. Data analysis was performed as previously described [Sun Y, Hu G, Liu H, Zhang X, Huang Z, Yan H, et al. Further delineation of the phenotype of truncating KMT2A mutations: the extended Wiedemann–Steiner syndrome. Am J Med Genet A. 2017;173:510–4.]. Multiplex ligation-dependent probe amplification analysis was performed for samples in which Sanger sequencing or WES failed to detect any disease-causing mutation.

      SupplementalData: Table 3, no therapy received, mutation inherited, family history, deceased

      Variant: NM_000531.6:c.579G>A

      ClinVarID: N/A

      CAID: CA412725369

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

    8. Case: Patient #59, female, Chinese

      DiseaseAssertion: UCD/OTCD

      FamilyInfo: variant in proband's mother and father

      CasePresentingHPOs: HP:0003621, HP:0001987, HP:0003218, HP:0003217

      CaseHPOFreeText:juvenile onset, hyperammonemia , oroticaciduria, hyperglutaminemia

      CaseNOTHPOs: N/A

      CaseNOTHPOFreeText: No neurological damage

      CasePreviousTesting: gDNA extracted from peripheral blood leukocytes. PCR all coding exons and exon–intron boundaries of the OTC gene using 9 pairs of synthetic oligonucleotide primers, and the primer sequences and annealing temperature. PCR products were then purified and bidirectionally sequenced. The library was sequenced using Illumina HiSeq4000 and generated 150 bp paired-end reads. Data analysis was performed as previously described [Sun Y, Hu G, Liu H, Zhang X, Huang Z, Yan H, et al. Further delineation of the phenotype of truncating KMT2A mutations: the extended Wiedemann–Steiner syndrome. Am J Med Genet A. 2017;173:510–4.]. Multiplex ligation-dependent probe amplification analysis was performed for samples in which Sanger sequencing or WES failed to detect any disease-causing mutation.

      SupplementalData: Table 3, drug treatment(L-arginine, L-Citrulline, sodium benzoate, and sodium phenylbutyrate)

      Variant: NM_000531.6:c.664-1G>A

      ClinVarID: 97288

      CAID: CA224737

      gnomAD:

      GeneName: OTC (ornithine transcarbamylase)

  17. Jun 2024
  18. May 2022
    1. DICER1 syndrome encompasses a variety of benign and malignant manifestations including multinodular goitre

      Gene: DICER1 PMCID: PMC8451242 PMID: 34552563 Pathogenic Inheritance Pattern: Autosomal Dominant MultipleDiseaseEntities Disease Entity: DICER1 syndrome, multinodular goitre, cystic nephroma, anaplastic renal sarcoma, Wilms tumour, differentiated thyroid carcinoma, gynandroblastoma, ciliary body medulloepithelioma, embryonal rhabdomyosarcoma, pineoblastoma, pituitary blastoma, kidney cyst, pulmonary cyst, Sertoli-Leydig Cell Tumor. Mutation: Germline MultipleGeneVariants Variant & Clinvar IDs: c.3452_3453del (485534), c.316del (no ClinVar ID), c.171_172insAC (no ClinVar ID), c.3434del (no ClinVar ID), c.988C>T (933007), c.5388dup (no ClinVar ID) Zygosity: None provided. Case: At time of operation, the goitre patients living in Denmark were ages 21, 12, 21, 8, 14, and 16. Four underwent total thyroidectomies, and two underwent partial thyroidectomies. The patient originally aged 21 previously had a kidney cyst at age 14 and a pulmonary cyst at an unknown age. The patient aged 14 at time of partial thyroidectomy later manifested a Sertoli-Leydig Cell Tumor at age 15. All six patients were female. CasePresentingHPO: None provided. CasePreviousTesting: thyroidectomy gnomAD: ENSG00000100697.10, https://gnomad.broadinstitute.org/gene/ENSG00000100697 Mutation Type: Frameshift, Nonsense

    1. DICER1 syndrome is a rare genetic disorder that predisposes individuals to multiple cancer types.

      GeneName: DICER1 PMID: 29762508 HGNCID: N/A Inheritance Pattern: Autosomal dominant Disease Entity: Cancer Mutation: Germline Zygosity: Heterozygosity Variant: Unregistered Family Information: 12% of children with pleuropulmonary blastomas have cystic nephromas Case: 11 year old patient with Hodgkin lymphoma with DICER1 mutation in 2016.

    1. DICER1 syndrome is an autosomal-dominant, pleiotropic, tumor-predisposition disorder arising from pathogenic germline variants in DICER1, which encodes an endoribonuclease integral to processing microRNAs (1).

      Gene Name: DICER1 PMCID: PMC5443331 PMID: 28323992 HGNCID: not found Inheritance Pattern: autosomal dominant Disease Entity: thyroid cancer and familial multinodular doiter Mutation: germline loss-of-function mutation Zygosity: not provided Variant: c.1870C>T; p.Arg624a, c.1870C>T; p.Arg624a, c.1870C>T; p.Arg624a, c.1870C>T; p.Arg624a, c.3726C>A; p.Tyr1242a, c.3675C>G; p.Tyr1225a, c.3675C>G; p.Tyr1225a Family Information: 145 individuals with a DICER1 germline mutation and 135 controls from 48 families Case: family members used; both males and females used and no significant differences seen among sex; ages range from 20-40 with carriers being significantly younger than controls; no significant differences seen among ethnicity but participants located from the US, UK, and Great Britain CasePresentingHPOs: thyroid cancer or MNG diagnosis common to those with a DICER! mutation but with no chemotherapy or radiation treatment yet CasePreviousTesting: tested levels of thyroid-stimulating hormone, thyroxine, thyroxine-binding globulin, and serum albumin; thyroid palpation; thyroid ultrasound; Sanger or next-generation sequencing assays gnomAD: n/a Mutation Type: missense

    1. DICER1 gene is located on chromosome 14q32.13 and plays a crucial role in the control of protein translation; its product, dicer protein, is a ribonuclease (RNase) III endoribonuclease which is essential for the production of microRNAs (miRNA) which are formed by the cleavage of pre-miRNA or double-stranded RNA1–4. RNase III contains two domains, IIIa and IIIb which cleave 3p miRNA and 5p miRNA from the 3′ and 5′ pre-miRNA, respectively. These cleavages require magnesium ions at the interface between the IIIa and IIIb domains and the miRNA; this magnesium dependent catalytic processing occurs at specific residues, E1320, E1564, E1813 and D17092–4. miRNA has a pivotal role in regulating the expression of over 30% of protein-coding genes by its interaction with mRNA5. Given the impact of DICER1 in post-translational events, it is not entirely surprising that functional DICER1 is essential for vertebrate development as evidenced by developmental arrest and death of the embryo when both alleles are lost6,7. Conceptually, DICER1 can be regarded as either a tumor suppressor gene due to loss-of-function mutations or an oncogene due to gain-of-function mutations; it is thought to function as a haploinsufficient tumor suppressor gene with the loss of one allele leading to tumor progression but loss of both alleles having an inhibitory effect for tumor development implying that one intact allele is needed for cell survival8.A study led by one of the authors (DAH) identified germline loss-of-function DICER1 mutations affecting the RNase IIIb domain in affected families with pleuropulmonary blastoma (PPB)9, a rare dysembryonic lung malignancy of childhood which was not the only manifestation of this familial tumor predisposition syndrome; germline and somatic DICER1 mutations were subsequently identified in several other familial associated tumors in several extrapulmonary sites (Table 1). Individuals with germline DICER1 mutations also had non-neoplastic conditions including macrocephaly, renal structural anomalies, retinal abnormalities, dental perturbations, and the GLOW syndrome (global developmental delay, lung cysts, overgrowth and Wilms tumor). These associations encircle the DICER1 tumor predisposition syndrome (Online Mendelian Inheritance in Man numbers 606241, 601200 and 138800), with the estimation that 90% of those affected by this syndrome inherited a germline mutation from one of their parents, with a pattern of autosomal dominant inheritance10.
      • Gene Name: DICER1 Syndrome (OMIM 606241, 601200)
      • PMID: 34599283
      • Hugo Gene Nomenclature Committee (HGNCID): N/A
      • Inheritance Pattern: Autosomal Dominant
      • Disease Entity: pleuropulmonary blastoma (PPB), Sertoli-Leydig cell tumor, gynandroblastoma, embryonal rhabdomyosarcomas of the cervix and other sites, multinodular goiter, differentiated and poorly differentiated thyroid carcinoma, cervical-thyroid teratoma, cystic nephroma-anaplastic sarcoma of kidney, nasal chondromesenchymal hamartoma, intestinal juvenile-like hamartomatous polyp, ciliary body medulloepithelioma, pituitary blastoma, pineoblastoma, primary central nervous system sarcoma, embryonal tumor with multilayered rosettes-like cerebellar tumor, PPB-like peritoneal sarcoma, DICER1-associated presacral malignant teratoid neoplasm and other non-neoplastic associations.
      • Mutation: Germline
      • Zygosity: Heterozygous
      • Variant: has multiple variants associated with it
      • Family Information: Germ cell tumors have been reported in family members
      • Case: identified affected families w/ pleuropulmonary blastoma (PPB): germline and somatic DICER1 mutations also identified in other familial associated tumors
      • CasePreviousTesting: numerous studies confirmed relationship b/t DICER1 variants in carriers and development of range neoplasms and non-neoplastic conditions
    1. DICER1 syndrome is an autosomal-dominant, familial pleiotropic tumor-predisposition disorder1 caused by pathogenic germline variants in DICER1, an essential component of the microRNA processing pathway.

      GeneName: DICER1 PMID: 30715996 HGNCID: N/A Inherritence pattern: autosomal dominant Disease Entity: multiple gene variants mutation: germline Zygosity: N/A Variant: Not found Family Info: N/A

    1. Pathogenic germline variants in DICER1 underlie an autosomal dominant, pleiotropic tumor-predisposition disorder.

      gene name: DICER 1 PMID (PubMed ID): 33570641 HGNCID: n/a Inheritance Pattern: autosomal dominant Disease Entity: benign and malignant tumor mutation Mutation: somatic Zygosity: heterozygous Variant: n/a Family Information: n/a Case: people of all sexes, ages, ethnicities and races participated CasePresentingHPOs: individuals with DICER1-associated tumors or pathogenic germline DICER1 variants were recruited to participate CasePreviousTesting: n/a gnomAD: n/a

    1. DICER1 syndrome is a rare genetic condition predisposing to hereditary cancer and caused by variants in the DICER1 gene.

      GeneName: DICER1 PMID: 33552988 HGNCID: Unavailable Inheritance Pattern: Autosomal Dominant with reduced penetrance Disease Entity: Cystic nephroma, familial pleuropulmonary blastoma (PPB), ovarian Sertoli-Leydig cell tumor (SLCT), cervix embryonal rhabdomyosarcoma, multinodular goiter, Wilms' Tumor, Ciliary body medulloepithelioma, nasal chondromesenchymal hamartoma, differentiated thyroid carcinoma, pituitary blastoma, pineoblastoma, sarcomas of different sites. Mutation: germline mutation Zygosity: heterozygous Variant: ClinVar ID not listed Family Information: No family cases listed Case: No specific case mentioned gnomAD: N/A Mutation Type: Frameshift, Nonsense mutation

    1. Germline pathogenic variation in DICER1 underlies a tumor-predisposition disorder with increased risk for cervical embryonal rhabdomyosarcoma and ovarian sex-cord stromal tumors, particularly Sertoli-Leydig cell tumors.
      • GeneName: DICER1
      • PMID (PubMed ID): 31952842
      • HGNCID: N/A
      • Inheritance Pattern: Autosomal dominant
      • Disease Entity: Ovarian Sertoli-Leydig cell tumors or gynandroblastoma; cervical embryonal rhabdomyosarcoma; pleuropulmonary blastomas; ovarian tumors generally presented with virilization and amenorrhea during adolescence; metachronous ovarian tumors; thyroid disease; increases risk of thyroid cancer during pregnancy
      • Mutation: Germline
      • Zygosity: Heterozygous
      • Variant: No variant
      • Family Information: The pleuropulmonary blastoma locus was mapped to chromosome 14q using linkage analysis in families with multiple cases of pleuropulmonary blastoma, resulting in the identification of heterozygous germline variants in DICER. Sixty-four DICER1-carrier female patients from 32 predominantly non-Hispanic white families were confirmed to have a heterozygous germline DICER1 pathogenic variant and ranged in age from 2–72 years (median: 31 years).